WO1996016694A1 - Automatic lead recognition for implantable medical device - Google Patents

Automatic lead recognition for implantable medical device Download PDF

Info

Publication number
WO1996016694A1
WO1996016694A1 PCT/US1995/014808 US9514808W WO9616694A1 WO 1996016694 A1 WO1996016694 A1 WO 1996016694A1 US 9514808 W US9514808 W US 9514808W WO 9616694 A1 WO9616694 A1 WO 9616694A1
Authority
WO
WIPO (PCT)
Prior art keywords
impedance
electrodes
lead
pacing
electrode
Prior art date
Application number
PCT/US1995/014808
Other languages
French (fr)
Inventor
John D. Wahlstrand
Daniel J. Baxter
R. Michael Ecker
Daniel R. Greeninger
Charles G. Yerich
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to AU44066/96A priority Critical patent/AU4406696A/en
Publication of WO1996016694A1 publication Critical patent/WO1996016694A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/37Monitoring; Protecting
    • A61N1/3706Pacemaker parameters

Definitions

  • This invention relates generally to the field of automatic, body-implantable medical device systems, and more particularly to implantable device systems including one or more electrically conductive leads.
  • a wide assortment of automatic, body-implantable medical devices are presently known and commercially available.
  • the class of such devices includes cardiac pacemakers, cardiac defibrillators and cardioverters, neural stimulators and many others.
  • cardiac pacemakers are electrical devices used to supplant some or all of an abnormal heart's natural pacing function. Pacemakers typically operate to deliver appropriately timed electrical stimulation signals, sometimes called pacing pulses, designed to cause the myocardium to contract or "beat.”
  • pacemakers are typically characterized according the chambers of the heart to which they are capable of delivering stimuli, and their responses, if any, to sensed intrinsic electrical cardiac activity. Some pacemakers, especially early ones, deliver pacing stimuli at fixed, regular intervals without regard to naturally occurring cardiac activity. More commonly at present, however, pacemakers sense electrical cardiac activity in one or both chambers of the heart, and inhibit or trigger delivery of pacing stimuli to the heart based upon the occurrence and recognition of such sensed intrinsic electrical events.
  • the Inter-Society Commission for Heart Diseases has established a standard three-letter descriptive code to characterize pacemakers.
  • the first letter of the ICHD code indicates which chambers of the heart the pacemaker is capable of pacing (atrial (A), ventricular (V), or atrial and ventricular (D)).
  • the second letter indicates which chambers of the heart the pacemaker is capable of sensing (A, N, or D), and the third letter indicates the response of the pacemaker to a sensed intrinsic event (triggered (T), inhibited (I), or dual (D)).
  • a VVI pacemaker for example, senses electrical cardiac activity only in the ventricle of a patients heart, and delivers pacing stimuli only in the absence of sensed electrical signals indicative of natural ventricular contractions (an "inhibited" response).
  • a DDD pacemaker senses electrical activity in both the atrium and ventricle of the heart (an “inhibited” response), and delivers atrial pacing stimuli only in the absence of sensed signals indicative of natural atrial contractions, and ventricular stimuli only in the absence of sensed signals indicative of natural ventricular contractions (an “inhibited” response).
  • the delivery of each stimulus by a DDD pacemaker is synchronized with prior sensed or paced events (a "triggered” response, and since the responses are also "inhibited” as noted above, the third letter in the ICHD code is "D").
  • CMOS complementary metal-oxide-semiconductor
  • CMOS complementary metal-oxide-semiconductor
  • the protective canister of the implanted device is conductive and functions as an electrode in pacing or sensing.
  • the current path for stimulating pulses extends from the pacemaker's pulse generator, along the lead to the exposed distal electrode, through the cardiac tissue, and back to the pacemaker via the conductive canister.
  • a lead having two mutually isolated conductors and two electrodes disposed thereon is required.
  • one electrode is disposed at the distal end of the lead and is referred to as the "tip" electrode, while the second electrode is spaced back somewhat from the distal end of the lead and is referred to as a "ring" electrode.
  • the current path for bipolar pacing extends from the pulse generator in the pacemaker, along a first of the two lead conductors to the tip electrode, through the cardiac tissue to the ring electrode, and back to the pacemaker along the second of the two lead conductors.
  • a fully-featured DDD pacemaker since it is capable of sensing and pacing in both chambers of the heart, can be programmed to operate in modes other than
  • DDD for example, WD, NVI, AAI, etc....
  • many state-of-the-art pacemakers can be programmed to operate in either unipolar or bipolar pacing and sensing modes. This gives the implanting physician considerable flexibility in configuring a pacing system to suit the particular needs of a given patient.
  • the physician or clinician can re-program the already implanted device to operate in different modes and with different pacing and sensing polarities in response to changes in the patient's needs and condition.
  • an implantable device such as a pacemaker with the ability to automatically and chronically distinguish between unipolar and bipolar leads coupled to it, and verify on an ongoing basis post-implant, the continued functionality of the leads.
  • the present invention is directed to a method and apparatus to be incorporated into an implantable device system for periodically performing a test to determine what type of pacing and sensing paths (i.e., unipolar or bipolar) are presently available to the device.
  • an implantable pacemaker capable of both unipolar and bipolar pacing and sensing in one or both chambers of the heart uses sub- threshold impedance measurements on all potentially available pace/sense paths (atrial unipolar and bipolar, ventricular unipolar and bipolar) to perform various lead recognition functions, including, in the preferred embodiment, automatic implant detection, automatic implant polarity configuration, automatic bipolar lead monitoring, and polarity programming confirmation.
  • automatic implant detection can be performed such that upon attachment of leads to the pacemaker and implantation in a patient, the system automatically detects characteristics of impedance on the pace/sense paths and determines that implantation has occurred. Then, the pacemaker can be automatically initialized to begin performing post-implant functions, for example, diagnostic functions, rate response function initialization, and the like, without physician intervention.
  • automatic polarity configuration is available allowing the pacemaker to self-adapt to desired polarity modes once the device ascertains what modes are available based upon the types of leads used in a particular application.
  • bipolar lead monitoring is carried out on a chronic, ongoing basis, such that lead failures, even intermittent ones or ones that occur long after implant, can be detected and responded to, thereby enhancing the efficacy and reliability of the system.
  • This monitoring can be configured to be asynchronous, or synchronized to sensed and/or paced events.
  • polarity programming confirmation is provided automatically upon initiation of a non-invasive programming session, such that improper programming of the device is prevented.
  • the various lead recognition functions achievable with the present invention each involve the delivery of sub-threshold voltage pulses on each of the potentially available pace/sense paths of the system, in order to make measurements of the impedance observed along each of those paths.
  • sub-threshold it is meant that the energy level of the pulses delivered for the purposes of measuring pace/sense path impedance is lower than the patients stimulation threshold energy levels that could evoke a cardiac response.
  • the impedance measurements are then assessed in relation to predetermined control values to determine whether each potential pace/sense path is actually available.
  • FIG 1 is an illustration of a pacemaker in accordance with one aspect of the present invention having been implanted in a conventional manner into a patient;
  • Figure 2 is a block diagram of the pacemaker from Figure 1 ;
  • FIG 3 is a block diagram of lead recognition circuitry incorporated into the pacemaker from Figure 1 ;
  • Figure 4 is an illustration of the waveform of subthreshold pulses delivered by the lead recognition circuitry from Figure 3 for the purpose of carrying out impedance measurement.
  • pacemaker 10 in accordance with one embodiment of the invention may be implanted in a patient 12.
  • pacemaker 10 is housed within a hermetically sealed, biologically inert outer canister, which may itself be conductive and thus serve as an indifferent electrode in the pacemaker's pacing/sensing circuit.
  • One or more pacemaker leads collectively identified with reference numeral 14 in Figure 1 are electrically coupled to pacemaker 10 in a conventional manner, extending into the patient's heart 16 via a vein 18.
  • disposed generally near the distal end of lead 14 are one or more exposed conductive electrodes for receiving electrical cardiac signals and or for delivering electrical pacing stimuli to heart 16.
  • lead 14 may be implanted with its distal end situated in either the atrium or ventricle of heart 16.
  • pacemaker 10 comprises a primary pacing/control circuit 20 and, in accordance with an important aspect of the present invention, a lead recognition circuit 22.
  • lead recognition circuit 22 may in one implementation of the invention be associated with circuitry for performing other pacemaker-related functions.
  • circuit 22 additionally comprises circuitry for supporting activity and/or minute ventilation sensing in a rate- responsive cardiac pacemaker.
  • Much of the circuitry associated with pacing control circuit 20 is of conventional design, in accordance, for example, with what is disclosed in U.S. Patent No. 5,052,388 to Sivula et al, entitled “Method and Apparatus for Implementing Activity Sensing in a Pulse Generator.”
  • the Sivula et al. '388 patent is hereby incorporated by reference herein in its entirety.
  • certain components of pacemaker 10 are purely conventional in their design and operation, such components will not be described herein in detail, as it is believed that design and implementation of such components would be a matter of routine to those of ordinary skill in the art.
  • pacing/control circuit 20 in Figure 2 includes sense amplifier circuitry 24, pacing output circuitry 26, a crystal clock 28, a random-access memory and read-only memory (RAM/ROM) unit 30, a central processing unit (CPU) 32, and a telemetry circuit 34, all of which are well-known in the art.
  • sense amplifier circuitry 24 pacing output circuitry 26
  • crystal clock 28 pacing output circuitry 26
  • RAM/ROM random-access memory and read-only memory
  • CPU central processing unit
  • telemetry circuit 34 all of which are well-known in the art.
  • Pacemaker 10 preferably includes an internal telemetry circuit 34 so that it is capable of being programmed by means of external programmer/control unit 17 (not shown in Figure 1). Programmers and telemetry systems suitable for use in the practice of the present invention have been well known for many years.
  • Known programmers typically communicate with an implanted device via a bi ⁇ directional radio-frequency telemetry link, so that the programmer can transmit control commands and operational parameter values to be received by the implanted device, and so that the implanted device can communicate diagnostic and operational data to the programmer.
  • Programmers believed to be suitable for the purposes of practicing the present invention include the Model 9760 and Model 9790 Programmers, commercially- available from Medtronic, Inc., Minneapolis, Minnesota.
  • Various telemetry systems for providing the necessary communications channels between an external programming unit and an implanted device have been developed and are well-known in the art. Telemetry systems believed to be suitable for the purposes of practicing the present invention are disclosed, for example, in the following U.S. Patents: U.S. Patent No.
  • telemetry systems such as those described in the above-referenced patents are employed in conjunction with an external programming/processing unit.
  • One programmer for non-invasively programming a cardiac pacemaker is described in the above-referenced Hartlaub et al. '884 patent.
  • telemetry systems for implantable medical devices employ a radio-frequency (RF) transmitter and receiver in the device, and a corresponding RF transmitter and receiver in the external programming unit.
  • the transmitter and receiver utilize a wire coil as an antenna for receiving downlink telemetry signals and for radiating RF signals for uplink telemetry.
  • the system is modelled as an air-core coupled transformer.
  • An example of such a telemetry system is shown in the above-referenced Thompson et al.
  • a digital encoding scheme such as is described in the above-reference Wyborny et al. '404 patent can be used.
  • a pulse interval modulation scheme may be employed, wherein the external programmer transmits a series of short RF "bursts" or pulses in which the interval between successive pulses (e.g., the interval from the trailing edge of one pulse to the trailing edge of the next) is modulated according to the data to be transmitted. For example, a shorter interval may encodes a digital "0" bit while a longer interval encodes a digital " 1 " bit.
  • a pulse position modulation scheme may be employed to encode uplink telemetry data.
  • a plurality of time slots are defined in a data frame, and the presence or absence of pulses transmitted during each time slot encodes the data.
  • a sixteen position data frame may be defined, wherein a pulse in one of the time slots represents a unique four bit portion of data.
  • programming units such as the above-referenced Medtronic Model 9760 and 9790 programmers typically interface with the implanted device through the use of a programming head or programming paddle, a handheld unit adapted to be placed on the patient's body over the implant site of the patient's implanted device.
  • a magnet in the programming head effects reed switch closure in the implanted device to initiate a telemetry session.
  • uplink and downlink communication takes place between the implanted device's transmitter and receiver and a receiver and transmitter disposed within the programming head.
  • pacemaker 10 is coupled to leads 14 which, when implanted, extend transvenously between the implant site of pacemaker 10 and the patient's heart 16, as previously noted with reference to Figure 1.
  • leads 14 will necessarily be coupled, either directly or indirectly, to sense amplifier circuitry 24 and pacing output circuit 26, in accordance with common practice, such that cardiac electrical signals may be conveyed to sensing circuitry 24, and pacing pulses may be delivered to cardiac tissue, via leads 14.
  • bipolar leads are employed ⁇ an atrial lead 14A having atrial tip and ring electrodes (ATJP and ARING in Figure 2), and a ventricular lead 14V having ventricular tip and ring electrodes (VTJP and VRING in Figure 2).
  • ARING atrial tip and ring electrodes
  • VRING ventricular tip and ring electrodes
  • a separate, electrically insulated conductor extending along the length of leads 14A and 14V is associated with each of the electrodes ATIP, ARING, VTIP, and VRING. That is, electrical signals applied, for example, to the VRING electrode are conducted along lead 14V on a first conductor (wire), whereas signals applied to the VTIP electrode are conducted along a second, separate, conductor in lead 14V.
  • the conductive hermetic canister 11 of pacemaker 10 serves as an indifferent electrode (CASE in Figure
  • pace/control circuit 20 includes central processing unit 32 which may be an off-the-shelf programmable microprocessor or microcontroller, but in the presently preferred embodiment of the invention is a custom integrated circuit.
  • CPU 32 functions to control the timed operation of pacing output circuit 26 and sense amplifier circuit 24 under control of programming stored in RAM ROM unit 30.
  • crystal oscillator circuit 28 in the presently preferred embodiment a 32,768-Hz crystal controlled oscillator, provides main timing clock signals to pace/control circuit 20 and to lead recognition circuit 22.
  • pacemaker 10 depicted in FIG. 1
  • pace/control circuit 20 is coupled to lead recognition circuit 22 by means of multiple signal lines, designated collectively as 38 in Figure 2.
  • An I/O interface 40 in pace/control circuit 20 and a corresponding I/O interface 42 in lead recognition circuit 22 function to coordinate the transmission of signals between the two units 20 and 22.
  • lead recognition circuit 22 includes a lead interface circuit 44, which essentially functions as a multiplexer to selectively couple the lead conductors associated with the ATIP, ARING, VTJP, and VRING electrodes of leads 14A and 14V to the remaining components of lead recognition circuitry 22.
  • the selection of particular conductors can accomplished by interface circuit 44 under control of control signals originating from pace/control circuit 20 and communicated to lead interface circuit 44 via lines 38.
  • excitation and sample circuit 50 Coupled to lead interface circuit 44 in lead recognition circuit 22 is an excitation and sample circuit 50 which, as will be hereinafter described in greater detail, functions to generate biphasic excitation pulses which are conveyed along leads 14A and/or 14V for the purposes of measuring impedance between various combinations of electrodes ATJP, ARING, VTIP, and VRING, as determined by the multiplexing function of lead interface circuit 44.
  • excitation and sample circuit 50 performs a sampling function on electrical signals present on the conductors of leads 14A and 14V.
  • logadc circuit 52 performs a logarithmic analog-to-digital conversion function on the sample values obtained by sample and excitation circuit 50, resulting in the derivation of values corresponding to the current and voltage on the conductors of leads 14A and 14V. These values, in turn, are used to derive an impedance value reflecting the PCIYUS95/14808
  • impedance associated with a given pacing path defined by the conductors of leads 14A and 14V is determined in a digital interface circuit 54 which also functions to coordinate the transfer of digital information between lead recognition circuit 22 and pace/control circuit 20 on lines 38.
  • an lead recognition voltage regulator (“lrreg”) circuit 56 is provided to define a reference voltage used by excitation and sample circuit 50.
  • FIG. 3 Another block diagram of lead recognition circuit 22 in accordance with the presently disclosed embodiment of the invention is provided in Figure 3.
  • the block diagram of Figure 3 is somewhat more detailed than that of Figure 2, in that it shows more of the individual connections between components of lead recognition circuit 22.
  • leads 14A and 14V extend between the patient's heart 16 and lead interface circuit 44. Since each lead 14A and 14V includes two separate internal conductors, leads 14A and 14V convey four separate electrical signals to lead interface circuit 44. Specifically, lead 14A conducts an atrial tip (AT) signal from its ATIP electrode and an atrial ring (AR) signal from its ARING electrode. Similarly, lead 14V conducts a ventricular tip (VT) signal and a ventricular ring (NR) signal from its VTIP and VRI ⁇ G electrodes, respectively. In addition, a signal C from the conductive case 11 of pacemaker 10, acting as an additional (fifth) electrode, is provided to interface circuit 44.
  • AT atrial tip
  • AR atrial ring
  • VT ventricular tip
  • NR ventricular ring
  • an atrial unipolar pacing/sensing path can be established wherein pacing pulses are delivered between one of the atrial tip electrode A ⁇ P and the conductive canister (CAN) electrode.
  • a atrial bipolar pacing/sensing path can be established, wherein pacing pulses are delivered between the ATIP and ARING electrodes of atrial lead 14A.
  • ventricular unipolar (VTIP-to-CASE) or bipolar (VTIP-to- VRING) pacing/sensing paths can be established.
  • the pacing and sensing paths for each chamber of heart 16 are programmably selectable post-implant.
  • pacemaker 10 may be capable of operating in either unipolar or bipolar pacing modes in each chamber, the implanting physician may determine that unipolar pacing is preferred in view of the patient's particular condition, and can program pacemaker 10 accordingly.
  • a pacemaker although operable in either unipolar or bipolar pacing/sensing modes, may be implanted with unipolar leads, thus making it impermissible for the pacemaker to be programmed into a bipolar mode.
  • the present invention relates to a method and apparatus for automatically detecting when the pacemaker has been implanted in a patient, with either unipolar or bipolar leads, and further for automatically detecting what types of leads have been coupled to the pacemaker at implant. This is accomplished through delivery of sub-threshold biphasic voltage pulses on the possible pacing/sensing paths (atrial unipolar and bipolar, ventricular unipolar and bipolar), such that the impedances observed along those paths can be evaluated.
  • excitation and sample circuit 50 includes circuitry for generating the small sub-threshold biphasic voltage pulses, which, through lead interface circuit 44 are periodically and sequentially issued along each of the four possible pacing paths.
  • An illustration of the biphasic pulse waveform generated by excitation and sample circuit 50 is shown in Figure 4.
  • the biphasic pulses have 0.26-V peak-to-peak amplitudes, and last for 30- ⁇ Sec (15- ⁇ Sec each phase).
  • the 0.26-V biphasic pulses are applied across the series combination of (1) a reference resistor, designated with reference numeral 53 in Figure 3, and (2) the resistance through the lead conductors and heart.
  • lead interface circuit 44 functions in a multiplexer-like capacity during a lead recognition measurement circuit to direct a biphasic pulse from excitation and sample circuit 50 to each of the four pacing paths. Thus, during each measurement cycle, up to four excitation pulses are delivered. When a pulse is delivered along a given path, the resulting current and voltage are measured.
  • lead recognition measurement cycles can be triggered either synchronously or asynchronously with respect to the patient's cardiac function.
  • Asynchronous measurement cycles occur once per second, while synchronous measurement cycles are initiated a predetermined time period following a paced or non-refractory sensed event in the chamber being measured.
  • synchronous mode measurements are synchronized off of cardiac events (sensed and paced), so that the frequency and timing within the cardiac cycle of the measurements is related to the pacing and intrinsic rate.
  • the predetermined delay period between detection of a sensed or paced cardiac event in a given cardiac chamber and delivery of sub-threshold pulse to that chamber may be among the programmably selectable parameters of pacemaker 10, in accordance with well-known practice in the art.
  • the voltage across reference resistor 53 is directly proportional to the current through the heart. After the sub-threshold pulse is delivered and the two resulting voltages are sampled, two multiple-cycle analog-to-digital conversions ensue. The conversions occur within logadc circuit 52 using the two sampled voltages available on the VIN and IIN lines. The VSEL control signal input to logadc circuit 52 selects between VIN and IIN. The result of each conversion appears at the LOGCOMP output as a serial bitstream.
  • digital interface circuit 54 For each sampling cycle of a given measurement cycle, digital interface circuit 54 produces two 7-bit digital values, VCODE and ICODE, from the serial bitstream provided by logadc circuit 52.
  • the VCODE and ICODE values reflect the logarithm of the voltage sample VIN and the logarithm of the current sample IIN, respectively.
  • These logarithmic values VCODE and ICODE are provided to digital interface circuit 54, where they are then subtracted, VCODE minus ICODE, to produce an impedance value ZCODE.
  • ZCODE is a logarithmic value, and is related to impedance observed on the path being measured as follows:
  • LEAD IMPEDANCE 500 x (1 + 0.0741 ) (ZC0DE
  • the ICODE and VCODE values have an absolute range from zero to 127 (seven bits). More realistic values in actual use are in the range from zero to 45, corresponding to voltages of 10.4- to 259.4-mV and currents of 20.8- to 518.8- ⁇ A on the path being measured.
  • the ZCODE value has an absolute range of -127 to +127 (eight bits), while the typical range is -32 to +45, corresponding to path impedances in the range from 50- to 12,500- ⁇ .
  • pace/control circuit 20 maintains a number of values in memory unit 30. Among these values are four path monitor values (a separate path monitor value is maintained for each of the four possible paths — atrial unipolar and bipolar, ventricular unipolar and bipolar). A path monitor status value is also maintained for each path, where the path monitor status value is an indicator of recent individual lead impedance measurements taken on the path to which it corresponds.
  • the resultant ZCODE value from each single path measurement is compared against two values, MINZ and MAXZ that correspond to normal lead impedances. If the measurement is greater than or equal to MINZ and less than or equal to MAXZ, the individual measurement is in-range; otherwise it is out-of-range.
  • each path monitor register is a 32-bit shift register; also, associated with each path monitor register is an out-of-range counter. Updating of the path monitors occurs as follows: For each path monitor update, a bit is shifted into the path monitor shift register. The bit will be 0 if the measurement is in range, and 1 if the measurement is out-of-range. If the bit shifted in is a 1, the out-of- range counter is incremented. If the bit shifted out is a 1, the out-of-range counter is decremented.
  • the path monitor shift register and out-of-range counter for each path form an
  • the status of the four path monitors is updated and evaluated. If the value of a path's out-of-range counter is equal to or greater than a predetermined (programmed) M value, the path monitor status register (which need be only 1-bit) is set to out-of-range; otherwise the path monitor status register is set to in- range.
  • initializing the path monitors involves setting all shift registers and out-of-range counters to contain all zeros, and setting all path monitor status bits to in-range.
  • Path monitors are preferably frozen during any programming session, as evidenced by any valid programmer downlink. A measurement cycle in progress upon initiation of a programming session will be terminated and path monitor updates will not be made.
  • telemetry circuit 34 issues a signal on a line 55 (see Figure 2) between telemetry circuit 34 and digital interface circuit 54 if RF signals are detected during a measurement cycle.
  • the signal on line 55 tells interface circuit 54 to disregard the measurement values if RF is detected during the measurement cycle.
  • Implant Detection involves automatically recognizing when implant has occurred, and is beneficial for the purpose of initiating other processes in pacemaker 10, such as rate- response initialization and diagnostic data collection.
  • Implant Polarity Configuration involves automatically configuring pacing and sensing polarities for each chamber based on the lead(s) implanted.
  • Lead Monitoring entails monitoring each lead impedance value in each chamber, and comparing the results against programmable range and sensitivity criteria to determine lead status. If the criteria are met, the time and date are recorded.
  • the Lead Monitor function may also involve automatically switching the pacing and sensing polarities from bipolar to unipolar (or vice versa) and/or providing a warning to a physician or clinician attempting to program the pacemaker to a bipolar pacing or sensing path when criteria for a viable bipolar path are not met.
  • Implant Detection and Lead Monitoring are never active at the same time. Two time periods can be thought to exist: implant time, where Implant Detection is in progress and Implant Polarity Configuration can be either enabled or disabled, and chronic time, where Lead Monitoring and its various options may be either enabled or disabled by means of the programming system.
  • the Implant Detection function has two states: On and Off/Complete. During Implant Detection, lead recognition measurements are preferably made asynchronously and the path monitors will be updated to reflect path status.
  • the Implant Detection function also preferably uses a count-down timer and the path monitor status registers to determine when implant has occurred. The count-down timer decrements once per second while the path monitors meet certain criteria, set forth below. If the criteria are not met, the timer resets itself to is maximum value.
  • the status of the path monitors are checked at the completion of each measurement cycle.
  • the current path monitor status combination is compared to the path monitor status combination from the previous measurement cycle. If the current path monitor status combination is not one of the three listed below or is not the same as the previous path monitor status combination, the time is reset to its maximum value.
  • Atrial Unipolar Path In-Range Ventricular Unipolar Path: In-Range Atrial Bipolar Path: In-Range
  • Atrial Unipolar Path In-Range Ventricular Unipolar Path: In-Range Atrial Bipolar Path: Out-Of-Range
  • Atrial Unipolar Path In-Range Ventricular Unipolar Path: In-Range Atrial Bipolar Path: In-Range
  • the count-down timer is preferably frozen.
  • the Implant Detection function terminates.
  • the bipolar path monitor status for each chamber is evaluated. If the bipolar path monitor status is in-range, the permanent pacing and sensing polarities for that chamber are set to or remain bipolar. If the bipolar path monitor status is out-of-range, the permanent pacing and sensing polarities for that chamber are set to or remain unipolar. The new polarities are put into effect at the start of the next pacing cycle.
  • Termination of the Implant Detection function can also cause the initiation of other pacemaker processes, as previously noted, including automatic initialization of rate-response function (which may involve accumulating patient data over a period of 18 time before activation of rate-response operation - see the above-referenced U.S. patent application by Yerich et al.
  • termination of the Implant Detection function also preferably causes reinitialization of all path monitors to in-range, loading of all path monitor shift registers with zeroes, and setting of all path monitor out-of- range counters to zero. If the Lead Monitor function is not enabled, all path monitors are frozen.
  • the Implant Detection function can be forced to complete via a command transmitted downlink from the external programmer. Likewise, the programmer can re- start Implant Detection.
  • Implant Polarity Configuration feature automatically sets pacing and sensing polarities individually for each chamber.
  • Implant Polarity Configuration can be operational only while Implant Detection is in progress, and can be individually programmed On or Off.
  • Implant Polarity Configuration uses the individual measurement cycle results acquired while Implant Detection is in progress, and each chamber is evaluated individually.
  • the permanent pacing and sensing polarities are set to or remain bipolar. If the most recent chamber bipolar path is out-of-range, the permanent pacing and sensing polarities are set to or remain unipolar. The new polarities are put into effect at the start of the next pacing cycle. The pacing and sensing polarity decision is made with each measurement cycle.
  • the Lead Monitor function can be programmed to either "On”, “On plus atrial polarity switch”, “On plus ventricular polarity switch”, or “On plus ventricular and atrial polarity switch.”
  • the monitor trip criteria for each chamber are evaluated separately at the end of each cycle following completion of path monitor status updates. If the atrial path monitor changes from in-range to out-of-range and the atrial pace and sense polarities are not both unipolar, the atrial trip criteria are met. Similarly, if the ventricular path monitor changes from in-range to out-of-range and the ventricular pace and sense polarities are not both unipolar, the ventricular trip criteria are met. /14808
  • a "trip-bit" maintained in memory by the pace/control circuitry 20 is set and a timestamp is recorded. 5 2. If the chamber polarity switch bit is set (i.e., if Bipolar Lead Monitor is enabled to "On plus atrial and/or ventricular polarity switch," as described above), the permanent pace and sense polarity will be set to unipolar for that chamber, starting at the beginning of the next pacing cycle.
  • Pacing Confirmation An additional function of pacemaker 10 in connection with its lead recognition 10 capability is Polarity Programming Confirmation, which may be enabled or disabled independently from the Implant Detect and Lead Monitor functions.
  • a single asynchronous lead recognition measurement cycle is initiated.
  • the ICODE and VCODE from that cycle are stored in a reserved memory location maintained by pacing/control circuit 15 20. These measured values are not used by the path monitors.
  • the programmer can then interrogate pacemaker 10 and use the stored ICODE and VCODE to verify that a chamber's bipolar path is in-range before allowing the programmer to request pacing or sensing bipolarity for a given chamber.
  • the most recent measurement results can be used as the Polarity Programming Confirmation data, combined with Path Monitor status to determine bipolar availability.
  • Still another embodiment of the invention contemplated by the inventors involves operation of the lead recognition functions synchronously with the device's 25 pacing and/or sensing functions.
  • lead recognition excitation pulses are delivered after a predetermined delay interval following paced and/or sensed events.
  • the predetermined delay may be swept through its available range (determined by hardware) to detect lead fractures or shorts which might not be discemable with a fixed delay interval. This may be desirable because the effects of such fractures or shorts may 30 be more or less discemable depending upon the amount of flex to the lead, which in turn is dependent upon cardiac activity.
  • lead recognition markers can be incorporated into the marker channel uplink (see the above- referenced Markowitz '382 patent).

Abstract

A method and apparatus for determining the availability of unipolar and/or bipolar pacing/sensing paths in a body-implantable cardiac pacing system. In one embodiment, a pacemaker system includes impedance monitoring circuitry for periodically measuring impedance between pairs of electrodes that are potentially available for pacing and/or sensing. This impedance monitoring circuitry includes circuitry for delivering excitation pulses between pairs of potentially available electrodes (including the pacemaker canister in the case of unipolar pacing or sensing), and for monitoring the current and voltage between those pairs of electrodes during delivery of an excitation pulse. Availability of a pair of electrodes for pacing and/or sensing is indicated if the impedance between a pair of electrodes is found to lie within a predetermined range. Detection of availability of a particular pair of electrodes is used initially as an indication that the pacing system has been implanted, and is also used to distinguish between unipolar and bipolar leads in the pacing system.

Description

C /US95/14808
1
AUTOMATIC LEAP RECOGNITION FOR IMPLANTABLE
MEDICAL DEVICE
FIELD QF THE INVENTION This invention relates generally to the field of automatic, body-implantable medical device systems, and more particularly to implantable device systems including one or more electrically conductive leads.
BACKGROUND OF THE INVENTION A wide assortment of automatic, body-implantable medical devices are presently known and commercially available. The class of such devices includes cardiac pacemakers, cardiac defibrillators and cardioverters, neural stimulators and many others.
In general, cardiac pacemakers are electrical devices used to supplant some or all of an abnormal heart's natural pacing function. Pacemakers typically operate to deliver appropriately timed electrical stimulation signals, sometimes called pacing pulses, designed to cause the myocardium to contract or "beat."
Known and commercially available pacemakers are typically characterized according the chambers of the heart to which they are capable of delivering stimuli, and their responses, if any, to sensed intrinsic electrical cardiac activity. Some pacemakers, especially early ones, deliver pacing stimuli at fixed, regular intervals without regard to naturally occurring cardiac activity. More commonly at present, however, pacemakers sense electrical cardiac activity in one or both chambers of the heart, and inhibit or trigger delivery of pacing stimuli to the heart based upon the occurrence and recognition of such sensed intrinsic electrical events. The Inter-Society Commission for Heart Diseases has established a standard three-letter descriptive code to characterize pacemakers. The first letter of the ICHD code indicates which chambers of the heart the pacemaker is capable of pacing (atrial (A), ventricular (V), or atrial and ventricular (D)). The second letter indicates which chambers of the heart the pacemaker is capable of sensing (A, N, or D), and the third letter indicates the response of the pacemaker to a sensed intrinsic event (triggered (T), inhibited (I), or dual (D)). A VVI pacemaker, for example, senses electrical cardiac activity only in the ventricle of a patients heart, and delivers pacing stimuli only in the absence of sensed electrical signals indicative of natural ventricular contractions (an "inhibited" response). A DDD pacemaker, on the other hand, senses electrical activity in both the atrium and ventricle of the heart (an "inhibited" response), and delivers atrial pacing stimuli only in the absence of sensed signals indicative of natural atrial contractions, and ventricular stimuli only in the absence of sensed signals indicative of natural ventricular contractions (an "inhibited" response). The delivery of each stimulus by a DDD pacemaker is synchronized with prior sensed or paced events (a "triggered" response, and since the responses are also "inhibited" as noted above, the third letter in the ICHD code is "D").
Many state-of-the-art pacemakers are capable of performing either unipolar or bipolar sensing and of pacing in either chamber of the heart. Unipolar pacing requires an elongate lead having only one insulated conductor therein and only one generally distal electrode disposed thereon. As will be appreciated by those of ordinary skill in the art, in most unipolar configurations, the protective canister of the implanted device is conductive and functions as an electrode in pacing or sensing. In particular, for unipolar pacing the current path for stimulating pulses extends from the pacemaker's pulse generator, along the lead to the exposed distal electrode, through the cardiac tissue, and back to the pacemaker via the conductive canister.
For bipolar pacing and/or sensing, on the other hand, a lead having two mutually isolated conductors and two electrodes disposed thereon is required. Typically, one electrode is disposed at the distal end of the lead and is referred to as the "tip" electrode, while the second electrode is spaced back somewhat from the distal end of the lead and is referred to as a "ring" electrode. The current path for bipolar pacing extends from the pulse generator in the pacemaker, along a first of the two lead conductors to the tip electrode, through the cardiac tissue to the ring electrode, and back to the pacemaker along the second of the two lead conductors.
Typically, a fully-featured DDD pacemaker, since it is capable of sensing and pacing in both chambers of the heart, can be programmed to operate in modes other than
DDD, for example, WD, NVI, AAI, etc.... In addition, many state-of-the-art pacemakers can be programmed to operate in either unipolar or bipolar pacing and sensing modes. This gives the implanting physician considerable flexibility in configuring a pacing system to suit the particular needs of a given patient. In addition, since most of today's pacemakers are non-invasively programmable post-implant, the physician or clinician can re-program the already implanted device to operate in different modes and with different pacing and sensing polarities in response to changes in the patient's needs and condition. •
Many pacemakers can accept and will operate with either unipolar or bipolar leads. Thus, it is important for the physician to be aware of which type of leads are used in a given instance, since it would be inappropriate to program the device into a bipolar pacing and/or sensing mode when only unipolar leads have been implanted. Similarly, if one of the two conductors or electrodes on an implanted bipolar lead were to fail for some reason (e.g., breakage of a conductor due to metal fatigue, poor connections between the lead and the pacemaker itself, tissue degradation at the electrode site, subclavian crushing of the lead, metal ion oxidation, short of lead conductors due to urethane/silicon breakdown, etc..) it would be necessary to re-program the pacemaker into unipolar pacing and sensing modes in order for the pacemaker to function properly. The need for such re-programming due to lead failure or improper initial programming, however, would only become apparent upon careful examination of the patient in a clinical setting, which may not occur frequently enough to ensure proper operation of the pacemaker over a long term of implant.
SUMMARY OF THE INVENTION
In view of the foregoing, it is believed by the inventors that it would be advantageous to endow an implantable device such as a pacemaker with the ability to automatically and chronically distinguish between unipolar and bipolar leads coupled to it, and verify on an ongoing basis post-implant, the continued functionality of the leads.
Thus, the present invention is directed to a method and apparatus to be incorporated into an implantable device system for periodically performing a test to determine what type of pacing and sensing paths (i.e., unipolar or bipolar) are presently available to the device.
In one embodiment of the invention, an implantable pacemaker capable of both unipolar and bipolar pacing and sensing in one or both chambers of the heart uses sub- threshold impedance measurements on all potentially available pace/sense paths (atrial unipolar and bipolar, ventricular unipolar and bipolar) to perform various lead recognition functions, including, in the preferred embodiment, automatic implant detection, automatic implant polarity configuration, automatic bipolar lead monitoring, and polarity programming confirmation.
In accordance with one aspect of the present invention, automatic implant detection can be performed such that upon attachment of leads to the pacemaker and implantation in a patient, the system automatically detects characteristics of impedance on the pace/sense paths and determines that implantation has occurred. Then, the pacemaker can be automatically initialized to begin performing post-implant functions, for example, diagnostic functions, rate response function initialization, and the like, without physician intervention.
In accordance with another aspect of the present invention, automatic polarity configuration is available allowing the pacemaker to self-adapt to desired polarity modes once the device ascertains what modes are available based upon the types of leads used in a particular application.
In accordance with yet another aspect of the invention, bipolar lead monitoring is carried out on a chronic, ongoing basis, such that lead failures, even intermittent ones or ones that occur long after implant, can be detected and responded to, thereby enhancing the efficacy and reliability of the system. This monitoring can be configured to be asynchronous, or synchronized to sensed and/or paced events.
In accordance with still another aspect of the invention, polarity programming confirmation is provided automatically upon initiation of a non-invasive programming session, such that improper programming of the device is prevented. The various lead recognition functions achievable with the present invention each involve the delivery of sub-threshold voltage pulses on each of the potentially available pace/sense paths of the system, in order to make measurements of the impedance observed along each of those paths. (By sub-threshold, it is meant that the energy level of the pulses delivered for the purposes of measuring pace/sense path impedance is lower than the patients stimulation threshold energy levels that could evoke a cardiac response.) The impedance measurements are then assessed in relation to predetermined control values to determine whether each potential pace/sense path is actually available.
RRΪFF DESCRIPTION OF THE DRAWINGS The foregoing and other aspects of the present invention will perhaps be best understood with reference to a detailed description of a particular embodiment of the invention, when read in conjunction with the accompanying drawings, wherein:
Figure 1 is an illustration of a pacemaker in accordance with one aspect of the present invention having been implanted in a conventional manner into a patient; Figure 2 is a block diagram of the pacemaker from Figure 1 ;
Figure 3 is a block diagram of lead recognition circuitry incorporated into the pacemaker from Figure 1 ; and
Figure 4 is an illustration of the waveform of subthreshold pulses delivered by the lead recognition circuitry from Figure 3 for the purpose of carrying out impedance measurement.
Although the present invention will be described herein with reference to a specific embodiment of the invention, namely, a dual-chamber, unipolar- and bipolar- capable pacemaker, it is contemplated that the present invention may be advantageously practiced in connection with other types of body-implantable medical device systems having multiple conductive paths potentially available for the purposes of performing sensing of electrical signals or delivery of electrical signals. It is believed that adaptation of the present invention as described herein to such other applications would be readily accomplished by those of ordinary skill in the art having the benefit of this disclosure.
DETAILED DESCRIPTION OF A SPECIFIC EMBODIMENT OF THE INVENTION
Referring to Figure 1, there is shown an illustration of generally where a pacemaker 10 in accordance with one embodiment of the invention may be implanted in a patient 12. In accordance with conventional practice in the art, pacemaker 10 is housed within a hermetically sealed, biologically inert outer canister, which may itself be conductive and thus serve as an indifferent electrode in the pacemaker's pacing/sensing circuit. One or more pacemaker leads, collectively identified with reference numeral 14 in Figure 1 are electrically coupled to pacemaker 10 in a conventional manner, extending into the patient's heart 16 via a vein 18. Disposed generally near the distal end of lead 14 are one or more exposed conductive electrodes for receiving electrical cardiac signals and or for delivering electrical pacing stimuli to heart 16. As will be appreciated by those of ordinary skill in the art, lead 14 may be implanted with its distal end situated in either the atrium or ventricle of heart 16.
Turning now to Figure 2, there is shown a block diagram of the electronic circuitry which makes up pacemaker 10 in accordance with the presently disclosed embodiment of the invention. As can be seen from Figure 2, pacemaker 10 comprises a primary pacing/control circuit 20 and, in accordance with an important aspect of the present invention, a lead recognition circuit 22. (It is contemplated by the inventors that the block designated lead recognition circuit 22 in Figure 2 may in one implementation of the invention be associated with circuitry for performing other pacemaker-related functions. For example, in one embodiment of the invention, circuit 22 additionally comprises circuitry for supporting activity and/or minute ventilation sensing in a rate- responsive cardiac pacemaker. Such an arrangement is described in co-pending U.S. patent application by Yerich et al. for a "Method and Apparatus for Rate Responsive Cardiac Pacing", filed as of the date of the present application and which is hereby incorporated by reference herein in its entirety. For the purposes of the present invention, however, only the circuitry in block 22 associated with the pacemaker's automatic lead recognition function will be described.
Much of the circuitry associated with pacing control circuit 20 is of conventional design, in accordance, for example, with what is disclosed in U.S. Patent No. 5,052,388 to Sivula et al, entitled "Method and Apparatus for Implementing Activity Sensing in a Pulse Generator." The Sivula et al. '388 patent is hereby incorporated by reference herein in its entirety. To the extent that certain components of pacemaker 10 are purely conventional in their design and operation, such components will not be described herein in detail, as it is believed that design and implementation of such components would be a matter of routine to those of ordinary skill in the art. For example, pacing/control circuit 20 in Figure 2 includes sense amplifier circuitry 24, pacing output circuitry 26, a crystal clock 28, a random-access memory and read-only memory (RAM/ROM) unit 30, a central processing unit (CPU) 32, and a telemetry circuit 34, all of which are well-known in the art.
Pacemaker 10 preferably includes an internal telemetry circuit 34 so that it is capable of being programmed by means of external programmer/control unit 17 (not shown in Figure 1). Programmers and telemetry systems suitable for use in the practice of the present invention have been well known for many years.
Known programmers typically communicate with an implanted device via a bi¬ directional radio-frequency telemetry link, so that the programmer can transmit control commands and operational parameter values to be received by the implanted device, and so that the implanted device can communicate diagnostic and operational data to the programmer. Programmers believed to be suitable for the purposes of practicing the present invention include the Model 9760 and Model 9790 Programmers, commercially- available from Medtronic, Inc., Minneapolis, Minnesota. Various telemetry systems for providing the necessary communications channels between an external programming unit and an implanted device have been developed and are well-known in the art. Telemetry systems believed to be suitable for the purposes of practicing the present invention are disclosed, for example, in the following U.S. Patents: U.S. Patent No. 5,127,404 to Wyborny et al. entitled "Telemetry Format for Implanted Medical Device"; U.S. Patent No. 4,374,382 to Markowitz entitled "Marker Channel Telemetry System for a Medical Device"; and U.S. Patent No. 4,556,063 to Thompson et al. entitled "Telemetry System for a Medical Device". The Wybomy et al. '404, Markowitz '382, and Thompson et al. '063 patents are commonly assigned to the assignee of the present invention, and are each hereby incorporated by reference herein in their respective entireties.
Typically, telemetry systems such as those described in the above-referenced patents are employed in conjunction with an external programming/processing unit. One programmer for non-invasively programming a cardiac pacemaker is described in the above-referenced Hartlaub et al. '884 patent. Most commonly, telemetry systems for implantable medical devices employ a radio-frequency (RF) transmitter and receiver in the device, and a corresponding RF transmitter and receiver in the external programming unit. Within the implantable device, the transmitter and receiver utilize a wire coil as an antenna for receiving downlink telemetry signals and for radiating RF signals for uplink telemetry. The system is modelled as an air-core coupled transformer. An example of such a telemetry system is shown in the above-referenced Thompson et al. '063 patent. In order to communicate digital data using RF telemetry, a digital encoding scheme such as is described in the above-reference Wyborny et al. '404 patent can be used. In particular, for downlink telemetry a pulse interval modulation scheme may be employed, wherein the external programmer transmits a series of short RF "bursts" or pulses in which the interval between successive pulses (e.g., the interval from the trailing edge of one pulse to the trailing edge of the next) is modulated according to the data to be transmitted. For example, a shorter interval may encodes a digital "0" bit while a longer interval encodes a digital " 1 " bit.
For uplink telemetry, a pulse position modulation scheme may be employed to encode uplink telemetry data. For pulse position modulation, a plurality of time slots are defined in a data frame, and the presence or absence of pulses transmitted during each time slot encodes the data. For example, a sixteen position data frame may be defined, wherein a pulse in one of the time slots represents a unique four bit portion of data.
As depicted in Figure 1, programming units such as the above-referenced Medtronic Model 9760 and 9790 programmers typically interface with the implanted device through the use of a programming head or programming paddle, a handheld unit adapted to be placed on the patient's body over the implant site of the patient's implanted device. A magnet in the programming head effects reed switch closure in the implanted device to initiate a telemetry session. Thereafter, uplink and downlink communication takes place between the implanted device's transmitter and receiver and a receiver and transmitter disposed within the programming head.
With continued reference to Figure 2, pacemaker 10 is coupled to leads 14 which, when implanted, extend transvenously between the implant site of pacemaker 10 and the patient's heart 16, as previously noted with reference to Figure 1. For the sake of clarity, the connections between leads 14 and the various components of pacemaker 10 are not shown in Figure 2, although it will be clear to those of ordinary skill in the art that, for example, leads 14 will necessarily be coupled, either directly or indirectly, to sense amplifier circuitry 24 and pacing output circuit 26, in accordance with common practice, such that cardiac electrical signals may be conveyed to sensing circuitry 24, and pacing pulses may be delivered to cardiac tissue, via leads 14.
In the presently disclosed embodiment, two bipolar leads are employed ~ an atrial lead 14A having atrial tip and ring electrodes (ATJP and ARING in Figure 2), and a ventricular lead 14V having ventricular tip and ring electrodes (VTJP and VRING in Figure 2). Those of ordinary skill in the art will appreciate that a separate, electrically insulated conductor extending along the length of leads 14A and 14V is associated with each of the electrodes ATIP, ARING, VTIP, and VRING. That is, electrical signals applied, for example, to the VRING electrode are conducted along lead 14V on a first conductor (wire), whereas signals applied to the VTIP electrode are conducted along a second, separate, conductor in lead 14V. In addition, as noted above, the conductive hermetic canister 11 of pacemaker 10 serves as an indifferent electrode (CASE in Figure
2). As previously noted, pace/control circuit 20 includes central processing unit 32 which may be an off-the-shelf programmable microprocessor or microcontroller, but in the presently preferred embodiment of the invention is a custom integrated circuit.
Although specific connections between CPU 32 and other components of pace/control circuit 20 are not shown in Figure 2, it will be apparent to those of ordinary skill in the art that CPU 32 functions to control the timed operation of pacing output circuit 26 and sense amplifier circuit 24 under control of programming stored in RAM ROM unit 30.
It is believed that those of ordinary skill in the art will be familiar with such an operative arrangement.
With continued reference to Figure 2, crystal oscillator circuit 28, in the presently preferred embodiment a 32,768-Hz crystal controlled oscillator, provides main timing clock signals to pace/control circuit 20 and to lead recognition circuit 22.
It is to be understood that the various components of pacemaker 10 depicted in
Figure 2 are powered by means of a battery (not shown) which is contained within the hermetic enclosure 11 of pacemaker 10, in accordance with common practice in the art. For the sake of clarity in the Figures, the battery and the connections between it and the other components of pacemaker 10 are not shown. Pacing output circuit 26, which functions to generate pacing stimuli under control of signals issued by CPU 32, may be, for example, of the type disclosed in U.S. Patent No. 4,476,868 to Thompson, entitled "Body Stimulator Output Circuit," which patent is hereby incorporated by reference herein in its entirety. Again, however, it is believed that those of ordinary skill in the art could select from among many various types of prior art pacing output circuits which would be suitable for the purposes of practicing the present invention.
As shown in Figure 2, pace/control circuit 20 is coupled to lead recognition circuit 22 by means of multiple signal lines, designated collectively as 38 in Figure 2. An I/O interface 40 in pace/control circuit 20 and a corresponding I/O interface 42 in lead recognition circuit 22 function to coordinate the transmission of signals between the two units 20 and 22.
With continued reference to Figure 2, lead recognition circuit 22 includes a lead interface circuit 44, which essentially functions as a multiplexer to selectively couple the lead conductors associated with the ATIP, ARING, VTJP, and VRING electrodes of leads 14A and 14V to the remaining components of lead recognition circuitry 22. In the preferred embodiment, the selection of particular conductors can accomplished by interface circuit 44 under control of control signals originating from pace/control circuit 20 and communicated to lead interface circuit 44 via lines 38. Coupled to lead interface circuit 44 in lead recognition circuit 22 is an excitation and sample circuit 50 which, as will be hereinafter described in greater detail, functions to generate biphasic excitation pulses which are conveyed along leads 14A and/or 14V for the purposes of measuring impedance between various combinations of electrodes ATJP, ARING, VTIP, and VRING, as determined by the multiplexing function of lead interface circuit 44. In addition, excitation and sample circuit 50 performs a sampling function on electrical signals present on the conductors of leads 14A and 14V.
The sample values obtained by excitation and sample circuit 50 are provided to a logarithmic analog-to-digital converter ("logadc") circuit 52. As its name suggests, logadc circuit 52 performs a logarithmic analog-to-digital conversion function on the sample values obtained by sample and excitation circuit 50, resulting in the derivation of values corresponding to the current and voltage on the conductors of leads 14A and 14V. These values, in turn, are used to derive an impedance value reflecting the PCIYUS95/14808
11
impedance associated with a given pacing path defined by the conductors of leads 14A and 14V. This impedance value is determined in a digital interface circuit 54 which also functions to coordinate the transfer of digital information between lead recognition circuit 22 and pace/control circuit 20 on lines 38. Finally, an lead recognition voltage regulator ("lrreg") circuit 56 is provided to define a reference voltage used by excitation and sample circuit 50.
Another block diagram of lead recognition circuit 22 in accordance with the presently disclosed embodiment of the invention is provided in Figure 3. The block diagram of Figure 3 is somewhat more detailed than that of Figure 2, in that it shows more of the individual connections between components of lead recognition circuit 22.
As shown in Figure 3, leads 14A and 14V extend between the patient's heart 16 and lead interface circuit 44. Since each lead 14A and 14V includes two separate internal conductors, leads 14A and 14V convey four separate electrical signals to lead interface circuit 44. Specifically, lead 14A conducts an atrial tip (AT) signal from its ATIP electrode and an atrial ring (AR) signal from its ARING electrode. Similarly, lead 14V conducts a ventricular tip (VT) signal and a ventricular ring (NR) signal from its VTIP and VRIΝG electrodes, respectively. In addition, a signal C from the conductive case 11 of pacemaker 10, acting as an additional (fifth) electrode, is provided to interface circuit 44. As will be familiar to those of ordinary skill in the art, the provision of two bipolar leads 14A and 14V, along with the use of the pacemaker's conductive canister as an additional electrode, allows a number of different pacing and sensing paths to be established in each chamber of the heart. In the atrial chamber, an atrial unipolar pacing/sensing path can be established wherein pacing pulses are delivered between one of the atrial tip electrode AΗP and the conductive canister (CAN) electrode. Alternatively, an atrial bipolar pacing/sensing path can be established, wherein pacing pulses are delivered between the ATIP and ARING electrodes of atrial lead 14A. Similarly, in the ventricular chamber, ventricular unipolar (VTIP-to-CASE) or bipolar (VTIP-to- VRING) pacing/sensing paths can be established. Typically, and in the preferred embodiment, the pacing and sensing paths for each chamber of heart 16 are programmably selectable post-implant. Thus, although pacemaker 10 may be capable of operating in either unipolar or bipolar pacing modes in each chamber, the implanting physician may determine that unipolar pacing is preferred in view of the patient's particular condition, and can program pacemaker 10 accordingly. It is also common that a pacemaker, although operable in either unipolar or bipolar pacing/sensing modes, may be implanted with unipolar leads, thus making it impermissible for the pacemaker to be programmed into a bipolar mode.
As noted in the Summary of the Invention above, the present invention relates to a method and apparatus for automatically detecting when the pacemaker has been implanted in a patient, with either unipolar or bipolar leads, and further for automatically detecting what types of leads have been coupled to the pacemaker at implant. This is accomplished through delivery of sub-threshold biphasic voltage pulses on the possible pacing/sensing paths (atrial unipolar and bipolar, ventricular unipolar and bipolar), such that the impedances observed along those paths can be evaluated.
To this end, and with continued reference to Figure 3, excitation and sample circuit 50 includes circuitry for generating the small sub-threshold biphasic voltage pulses, which, through lead interface circuit 44 are periodically and sequentially issued along each of the four possible pacing paths. An illustration of the biphasic pulse waveform generated by excitation and sample circuit 50 is shown in Figure 4. As shown in Figure 4, the biphasic pulses have 0.26-V peak-to-peak amplitudes, and last for 30-μSec (15-μSec each phase). The 0.26-V biphasic pulses are applied across the series combination of (1) a reference resistor, designated with reference numeral 53 in Figure 3, and (2) the resistance through the lead conductors and heart. It is believed that the biphasic nature of the sub-threshold pulses offers the advantages over a monophasic pulse that the peak amplitude of each pulse is minimized given the overall energy content of the pulse, electrode polarization is canceled, and DC current is balanced to avoid long-term lead metal-ion oxidation. It is believed that the implementation of circuitry for generating pulses such as depicted in Figure 4 would be a matter of routine engineering to those of ordinary skill in the art; therefore, the details of such circuitry will not be described further herein.
Returning to Figure 3, lead interface circuit 44 functions in a multiplexer-like capacity during a lead recognition measurement circuit to direct a biphasic pulse from excitation and sample circuit 50 to each of the four pacing paths. Thus, during each measurement cycle, up to four excitation pulses are delivered. When a pulse is delivered along a given path, the resulting current and voltage are measured.
In the presently preferred embodiment of the invention, lead recognition measurement cycles can be triggered either synchronously or asynchronously with respect to the patient's cardiac function. Asynchronous measurement cycles occur once per second, while synchronous measurement cycles are initiated a predetermined time period following a paced or non-refractory sensed event in the chamber being measured. In the presently preferred embodiment, synchronous mode measurements are synchronized off of cardiac events (sensed and paced), so that the frequency and timing within the cardiac cycle of the measurements is related to the pacing and intrinsic rate. The predetermined delay period between detection of a sensed or paced cardiac event in a given cardiac chamber and delivery of sub-threshold pulse to that chamber may be among the programmably selectable parameters of pacemaker 10, in accordance with well-known practice in the art. As noted above, when a sub-threshold biphasic pulse is delivered on a given path, the resultant voltage and current on that path are monitored. To this end, excitation and sample circuit 50 includes circuitry for obtaining samples of the voltage and current on the path being measured. In the presently preferred embodiment of the invention, the sampling rate is programmable, although the rate presently preferred is 1- Hz (i.e., one sample each second on each output/sensing path). For each measurement, the peak-to-peak voltage across the heart leads and the peak-to-peak voltage across reference resistor 53 are simultaneously sampled. Reference resistor 53 is configured in series with the heart so that the reference resistor's current is equal to that delivered to the heart. The voltage across reference resistor 53 is directly proportional to the current through the heart. After the sub-threshold pulse is delivered and the two resulting voltages are sampled, two multiple-cycle analog-to-digital conversions ensue. The conversions occur within logadc circuit 52 using the two sampled voltages available on the VIN and IIN lines. The VSEL control signal input to logadc circuit 52 selects between VIN and IIN. The result of each conversion appears at the LOGCOMP output as a serial bitstream.
For each sampling cycle of a given measurement cycle, digital interface circuit 54 produces two 7-bit digital values, VCODE and ICODE, from the serial bitstream provided by logadc circuit 52. The VCODE and ICODE values reflect the logarithm of the voltage sample VIN and the logarithm of the current sample IIN, respectively. These logarithmic values VCODE and ICODE are provided to digital interface circuit 54, where they are then subtracted, VCODE minus ICODE, to produce an impedance value ZCODE.
ZCODE is a logarithmic value, and is related to impedance observed on the path being measured as follows:
LEAD IMPEDANCE (in ohms) = 500 x (1 + 0.0741 )(ZC0DE| The ICODE and VCODE values have an absolute range from zero to 127 (seven bits). More realistic values in actual use are in the range from zero to 45, corresponding to voltages of 10.4- to 259.4-mV and currents of 20.8- to 518.8-μA on the path being measured. The ZCODE value has an absolute range of -127 to +127 (eight bits), while the typical range is -32 to +45, corresponding to path impedances in the range from 50- to 12,500-Ω. The ICODE and VCODE values derived during each sampling cycle of each measurement cycle are supplied via I/O lines 38 to pace/control circuit 20, where CPU 32 computes the corresponding ZCODE value. To support the lead recognition function in pacemaker 10, pace/control circuit 20 maintains a number of values in memory unit 30. Among these values are four path monitor values (a separate path monitor value is maintained for each of the four possible paths — atrial unipolar and bipolar, ventricular unipolar and bipolar). A path monitor status value is also maintained for each path, where the path monitor status value is an indicator of recent individual lead impedance measurements taken on the path to which it corresponds.
The resultant ZCODE value from each single path measurement is compared against two values, MINZ and MAXZ that correspond to normal lead impedances. If the measurement is greater than or equal to MINZ and less than or equal to MAXZ, the individual measurement is in-range; otherwise it is out-of-range.
Individual path monitor values in the path monitor registers are updated after both measurements for a given chamber have occurred during a measurement cycle. If both the bipolar path measurement and the unipolar path measurement for a given chamber are out-of-range, the updates for the two path monitors for that chamber are skipped. Otherwise, each path monitor uses the single measurement range result to update the individual path monitor status.
In the presently preferred embodiment, each path monitor register is a 32-bit shift register; also, associated with each path monitor register is an out-of-range counter. Updating of the path monitors occurs as follows: For each path monitor update, a bit is shifted into the path monitor shift register. The bit will be 0 if the measurement is in range, and 1 if the measurement is out-of-range. If the bit shifted in is a 1, the out-of- range counter is incremented. If the bit shifted out is a 1, the out-of-range counter is decremented. The path monitor shift register and out-of-range counter for each path form an
M-of-N monitor, where M is the number of measurements out of range over the last N measurements (N being the size in bits of the path monitor shift register).
For each measurement cycle, the status of the four path monitors is updated and evaluated. If the value of a path's out-of-range counter is equal to or greater than a predetermined (programmed) M value, the path monitor status register (which need be only 1-bit) is set to out-of-range; otherwise the path monitor status register is set to in- range. (In the presently preferred embodiment, initializing the path monitors involves setting all shift registers and out-of-range counters to contain all zeros, and setting all path monitor status bits to in-range.) Path monitors are preferably frozen during any programming session, as evidenced by any valid programmer downlink. A measurement cycle in progress upon initiation of a programming session will be terminated and path monitor updates will not be made.
In the presently preferred embodiment of the invention, telemetry circuit 34 issues a signal on a line 55 (see Figure 2) between telemetry circuit 34 and digital interface circuit 54 if RF signals are detected during a measurement cycle. The signal on line 55 tells interface circuit 54 to disregard the measurement values if RF is detected during the measurement cycle. This feature provides a desired level of immunity to RF downlink, since downlink RF bursts can induce energy on the lead system and confound the measurement.
The lead recognition feature of pacemaker 10 as thus far described may be advantageously utilized for several distinct functions: Implant Detection, Implant Polarity Configuration, Lead Monitoring, and Polarity Programming Confirmation. Implant Detection involves automatically recognizing when implant has occurred, and is beneficial for the purpose of initiating other processes in pacemaker 10, such as rate- response initialization and diagnostic data collection. Implant Polarity Configuration involves automatically configuring pacing and sensing polarities for each chamber based on the lead(s) implanted. Lead Monitoring entails monitoring each lead impedance value in each chamber, and comparing the results against programmable range and sensitivity criteria to determine lead status. If the criteria are met, the time and date are recorded. The Lead Monitor function may also involve automatically switching the pacing and sensing polarities from bipolar to unipolar (or vice versa) and/or providing a warning to a physician or clinician attempting to program the pacemaker to a bipolar pacing or sensing path when criteria for a viable bipolar path are not met.
Each of the above-described lead recognition functions can preferably be individually enabled and disabled. Implant Detection and Lead Monitoring are never active at the same time. Two time periods can be thought to exist: implant time, where Implant Detection is in progress and Implant Polarity Configuration can be either enabled or disabled, and chronic time, where Lead Monitoring and its various options may be either enabled or disabled by means of the programming system.
The Implant Detection function has two states: On and Off/Complete. During Implant Detection, lead recognition measurements are preferably made asynchronously and the path monitors will be updated to reflect path status. The Implant Detection function also preferably uses a count-down timer and the path monitor status registers to determine when implant has occurred. The count-down timer decrements once per second while the path monitors meet certain criteria, set forth below. If the criteria are not met, the timer resets itself to is maximum value.
The status of the path monitors are checked at the completion of each measurement cycle. The current path monitor status combination is compared to the path monitor status combination from the previous measurement cycle. If the current path monitor status combination is not one of the three listed below or is not the same as the previous path monitor status combination, the time is reset to its maximum value.
In the presently preferred dual-chamber embodiment of the invention, the three valid path monitor status combinations are as follows: Atrial Unipolar Path: In-Range Ventricular Unipolar Path: In-Range Atrial Bipolar Path: In-Range
Ventricular Bipolar Path: Out-Of-Range
Atrial Unipolar Path: In-Range Ventricular Unipolar Path: In-Range Atrial Bipolar Path: Out-Of-Range
Ventricular Bipolar Path: In-Range
Atrial Unipolar Path: In-Range Ventricular Unipolar Path: In-Range Atrial Bipolar Path: In-Range
Ventricular Bipolar Path: In-Range
(The foregoing valid path monitor status combinations are specific to a particular bipolar pacemaker system. It is believed that those of ordinary skill in the art would comprehend that different combinations might be considered valid depending upon the particular pacing system with which the present invention is practiced.) If Implant Detection is in progress and a programming session is initiated, the count-down timer is preferably frozen.
When the Implant Detection count-down timer reaches zero, the Implant Detection function terminates. At this time, if Implant Polarity Configuration is enabled, the bipolar path monitor status for each chamber is evaluated. If the bipolar path monitor status is in-range, the permanent pacing and sensing polarities for that chamber are set to or remain bipolar. If the bipolar path monitor status is out-of-range, the permanent pacing and sensing polarities for that chamber are set to or remain unipolar. The new polarities are put into effect at the start of the next pacing cycle.
Termination of the Implant Detection function can also cause the initiation of other pacemaker processes, as previously noted, including automatic initialization of rate-response function (which may involve accumulating patient data over a period of 18 time before activation of rate-response operation - see the above-referenced U.S. patent application by Yerich et al.
If the Lead Monitor function is enabled, termination of the Implant Detection function also preferably causes reinitialization of all path monitors to in-range, loading of all path monitor shift registers with zeroes, and setting of all path monitor out-of- range counters to zero. If the Lead Monitor function is not enabled, all path monitors are frozen.
The Implant Detection function can be forced to complete via a command transmitted downlink from the external programmer. Likewise, the programmer can re- start Implant Detection.
The Implant Polarity Configuration feature automatically sets pacing and sensing polarities individually for each chamber. Implant Polarity Configuration can be operational only while Implant Detection is in progress, and can be individually programmed On or Off. Implant Polarity Configuration uses the individual measurement cycle results acquired while Implant Detection is in progress, and each chamber is evaluated individually.
For Implant Polarity Configuration, if the most recent chamber bipolar measurement is in-range, the permanent pacing and sensing polarities are set to or remain bipolar. If the most recent chamber bipolar path is out-of-range, the permanent pacing and sensing polarities are set to or remain unipolar. The new polarities are put into effect at the start of the next pacing cycle. The pacing and sensing polarity decision is made with each measurement cycle.
The Lead Monitor function can be programmed to either "On", "On plus atrial polarity switch", "On plus ventricular polarity switch", or "On plus ventricular and atrial polarity switch." When Lead Monitor is active, the monitor trip criteria for each chamber are evaluated separately at the end of each cycle following completion of path monitor status updates. If the atrial path monitor changes from in-range to out-of-range and the atrial pace and sense polarities are not both unipolar, the atrial trip criteria are met. Similarly, if the ventricular path monitor changes from in-range to out-of-range and the ventricular pace and sense polarities are not both unipolar, the ventricular trip criteria are met. /14808
19
When a given chamber's trip criteria is met, as set forth above, the following actions are taken:
1. A "trip-bit" maintained in memory by the pace/control circuitry 20 is set and a timestamp is recorded. 5 2. If the chamber polarity switch bit is set (i.e., if Bipolar Lead Monitor is enabled to "On plus atrial and/or ventricular polarity switch," as described above), the permanent pace and sense polarity will be set to unipolar for that chamber, starting at the beginning of the next pacing cycle.
An additional function of pacemaker 10 in connection with its lead recognition 10 capability is Polarity Programming Confirmation, which may be enabled or disabled independently from the Implant Detect and Lead Monitor functions. At the start of a programming session, a single asynchronous lead recognition measurement cycle is initiated. At the completion of the measurement cycle, the ICODE and VCODE from that cycle are stored in a reserved memory location maintained by pacing/control circuit 15 20. These measured values are not used by the path monitors. The programmer can then interrogate pacemaker 10 and use the stored ICODE and VCODE to verify that a chamber's bipolar path is in-range before allowing the programmer to request pacing or sensing bipolarity for a given chamber.
(In an alternative implementation of the Polarity Programming Confirmation 20 function, the most recent measurement results can be used as the Polarity Programming Confirmation data, combined with Path Monitor status to determine bipolar availability.)
Still another embodiment of the invention contemplated by the inventors involves operation of the lead recognition functions synchronously with the device's 25 pacing and/or sensing functions. In this embodiment, lead recognition excitation pulses are delivered after a predetermined delay interval following paced and/or sensed events. The predetermined delay may be swept through its available range (determined by hardware) to detect lead fractures or shorts which might not be discemable with a fixed delay interval. This may be desirable because the effects of such fractures or shorts may 30 be more or less discemable depending upon the amount of flex to the lead, which in turn is dependent upon cardiac activity. In one embodiment of the invention contemplated by the inventors, lead recognition markers can be incorporated into the marker channel uplink (see the above- referenced Markowitz '382 patent).
From the foregoing detailed description of a specific embodiment of the invention, it should be apparent that a method and apparatus for providing a body- implantable medical device with the capability of recognizing the presence or absence of conductive leads coupled thereto through impedance measurement has been disclosed, and further that applications of this capability to provide such automatic implant detection, automatic implant polarity configuration, automatic and chronic bipolar lead monitoring, and polarity programming confirmation have been disclosed.

Claims

T/US95/1480821In the Claims:
1. A body-implantable cardiac pacemaker system and electronic circuitry housed therein, said system comprising: a hermetic enclosure for housing electronic circuitry; a flexible, elongate pacing sensing lead having at least one conductor therein extending between proximal and distal ends of said lead, said at least one conductor being coupled at said proximal end to said electronic circuitry in said hermetic enclosure and coupled generally near said distal end to a first conductive electrode adapted to be disposed in electrical contact with said patient's cardiac tissue; a second electrode, electrically coupled to said electronic circuitry in said hermetic enclosure, such that a current path is established extending from said electronic circuitry, along said at least one lead to said electrode, through a portion of said patient's body tissue to said second electrode and back to said electronic circuitry; wherein said electronic circuitry comprises: a sub-threshold excitation circuit coupled to said at least one conductor, for applying a sub-threshold excitation voltage pulse along said current path; an impedance measurement circuit, coupled to said at least one conductor and to said second electrode, adapted to measure impedance along said current path during application of said sub- threshold excitation voltage pulse, a comparison circuit, coupled to said impedance measurement circuit and adapted to determine whether said measured impedance lies within a predetermined impedance range, indicating the availability of said current path for cardiac pacing and wherein said impedance measurement circuit comprises: a sampling circuit for obtaining both a sample of voltage and of current between said first and second electrodes during said application of said sub- threshold excitation pulse; /US95/14808
22 an analog-to-digital converter for deriving a digital voltage value corresponding to the logarithm of said sampled voltage and a digital current value corresponding to the logarithm of said sampled current; and having an impedance computation circuit for deriving from said digital voltage and current 5 values a digital impedance value corresponding to the logarithm of the impedance between said first and second electrodes during application of said sub-threshold excitation pulse. 2. A system in accordance with claim 1, wherein said analog-to-digital converter is a logarithmic analog-to-digital converter. 10
3. A system in accordance with claim 1, wherein said excitation circuit applies said sub-threshold voltage pulse asynchronously with respect to paced and sensed cardiac activity.
4. A system in accordance with claim 1, wherein said excitation circuit applies said sub-threshold voltage pulse synchronously with respect to a sensed or paced
15 cardiac event.
5. In a cardiac pacing system comprising an implantable hermetic enclosure containing electronic circuitry and at least two electrodes coupled to said electronic circuitry, a method to detect availability of a current path between two of said at least two electrodes for cardiac pacing, said method comprising the steps of: 0 (a) delivering a sub-threshold excitation pulse between two of said at least two electrodes;
(b) monitoring, substantially at the time of said application of sub-threshold excitation pulse, impedance between said two electrodes by measuring both voltage and current and deriving impedance from these 5 measurements;
(c) determining whether said monitored impedance lies within a predetermined range, indicating availability of a current path for cardiac pacing between said two electrodes.
6. A method in accordance with claim 5, wherein in step (a) said sub- 0 threshold exitation pulse is delivered between a first of said two electrodes disposed generally at a distal end of an implanted lead and a second of said two electrodes being said hermetic enclosure.
7. A method in accordance with claim 5, wherein in step (a) said sub- threshold exitation pulse is delivered between a first of said two electrodes disposed at distal end of an implanted lead and a second of said two electrodes disposed at a point spaced back from said distal end of said lead.
8. A method in accordance with claim 5, wherein said step (a) of delivering an excitation pulse occurs asynchronously with respect to paced and sensed cardiac events.
9. A method in accordance with claim 5, wherein said step (a) of delivering excitation pulse occurs synchronously with respect to a paced or sensed cardiac event.
10. A method for automatically detecting implantation of a pacemaker system having at least two pacing/sensing electrodes, comprising the steps of:
(a) delivering an excitation pulse between two of said at least two electrodes;
(b) monitoring, during application of said excitation pulse, impedance between said two electrodes; (c) determining whether said monitored impedance lies within a predetermined range, indicating that said pacemaker system has been implanted.
11. A method in accordance with claim 10, wherein said step (a) of delivering an excitation pulse occurs asynchronously with respect to paced and sensed cardiac events.
12. A method in accordance with claim 10, wherein said step (a) of delivering an excitation pulse occurs synchronously with respect to a paced or sensed cardiac event.
13. A method in accordance with claim 12, wherein said step (a) of delivering an excitation pulse occurs at a predetermined interval following a paced or sensed cardiac event.
14. A method in accordance with claim 13, wherein said steps (a) through (c) are performed a plurality of times, and wherein said predetermined interval is varied after each performance of step (a).
15. A method for chronic monitoring of integrity of leads in a pacemaker system having at least two pacing/sensing electrodes, comprising the steps of:
(a) delivering an excitation pulse between two of said at least two electrodes; (b) monitoring, during application of said excitation pulse, impedance between said two electrodes;
(c) determining whether said monitored impedance lies within a predetermined range, indicating lead integrity; and (d) repeating steps (a) through (c) periodically.
16. A body-implantable cardiac pacemaker system, comprising: a hermetic enclosure for housing electronic circuitry; a flexible, elongate pacing sensing lead having at least one conductor therein extending between proximal and distal ends of said lead, said at least one conductor being coupled at said proximal end to said electronic circuitry in said hermetic enclosure and coupled generally near said distal end to a first conductive electrode adapted to be disposed in electrical contact with said patient's cardiac tissue; a second electrode, electrically coupled to said electronic circuitry in said hermetic enclosure, such that a current path is established extending from said electronic circuitry, along said at least one lead to said electrode, through a portion of said patient's body tissue to said second electrode and back to said electronic circuitry; wherein said electronic circuitry comprises: an excitation circuit coupled to said at least one conductor, for applying a sub-threshold symmetrical and bi-phasic voltage pulse along said current path; an impedance measurement circuit, coupled to said at least one conductor and to said second electrode, adapted to measure impedance along said current path during application of said sub- threshold voltage pulse a comparison circuit, coupled to said impedance measurement circuit and adapted to determine whether said measured impedance lies within a predetermined impedance range, indicating the availability of said current path for cardiac pacing.
17. A pacemaker system in accordance with claim 16, wherein said first electrode is disposed at the distal end of said lead and said second electrode is disposed on said lead at a point spaced back from said distal end, said second electrode being coupled to said electronic circuitry via a conductor extending along the length of said lead.
18. A pacemaker system in accordance with claim 16, wherein said hermetic enclosure is conductive and serves as said second electrode.
19. A pacemaker system in accordance with claim 16, wherein said impedance measurement circuit comprises: a sampling circuit for obtaining a sample of voltage between said first and second electrodes during said application of said excitation pulse and for obtaining a sample of current between said first and second electrodes during said application of said excitation pulse; an analog-to-digital converter for deriving a digital voltage value corresponding to the logarithm of said sampled voltage and a digital current value corresponding to the logarithm of said sampled current; and an impedance computation circuit for deriving from said digital voltage and current values a digital impedance value corresponding to the logarithm of the impedance between said first and second electrodes during application of said excitation pulse.
20. A pacemaker as in claim 16 wherein said pulse is on the order of .26 volts, peak to peak.
PCT/US1995/014808 1994-11-30 1995-11-13 Automatic lead recognition for implantable medical device WO1996016694A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44066/96A AU4406696A (en) 1994-11-30 1995-11-13 Automatic lead recognition for implantable medical device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/346,661 1994-11-30
US08/346,661 US5534018A (en) 1994-11-30 1994-11-30 Automatic lead recognition for implantable medical device

Publications (1)

Publication Number Publication Date
WO1996016694A1 true WO1996016694A1 (en) 1996-06-06

Family

ID=23360464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014808 WO1996016694A1 (en) 1994-11-30 1995-11-13 Automatic lead recognition for implantable medical device

Country Status (3)

Country Link
US (1) US5534018A (en)
AU (1) AU4406696A (en)
WO (1) WO1996016694A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1913971A1 (en) * 2006-10-20 2008-04-23 BIOTRONIK CRM Patent AG Implantable cardiac device with a shock lead
WO2008130409A1 (en) 2007-04-20 2008-10-30 Medtronic, Inc. Implantable medical electrical lead and connector assembly
US9186499B2 (en) 2009-04-30 2015-11-17 Medtronic, Inc. Grounding of a shield within an implantable medical lead
US9259572B2 (en) 2007-04-25 2016-02-16 Medtronic, Inc. Lead or lead extension having a conductive body and conductive body contact
US9302101B2 (en) 2004-03-30 2016-04-05 Medtronic, Inc. MRI-safe implantable lead
US9463317B2 (en) 2012-04-19 2016-10-11 Medtronic, Inc. Paired medical lead bodies with braided conductive shields having different physical parameter values
US9731119B2 (en) 2008-03-12 2017-08-15 Medtronic, Inc. System and method for implantable medical device lead shielding
US9993638B2 (en) 2013-12-14 2018-06-12 Medtronic, Inc. Devices, systems and methods to reduce coupling of a shield and a conductor within an implantable medical lead
US10084250B2 (en) 2005-02-01 2018-09-25 Medtronic, Inc. Extensible implantable medical lead
US10155111B2 (en) 2014-07-24 2018-12-18 Medtronic, Inc. Methods of shielding implantable medical leads and implantable medical lead extensions
US10279171B2 (en) 2014-07-23 2019-05-07 Medtronic, Inc. Methods of shielding implantable medical leads and implantable medical lead extensions
US10398893B2 (en) 2007-02-14 2019-09-03 Medtronic, Inc. Discontinuous conductive filler polymer-matrix composites for electromagnetic shielding

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136019A (en) * 1996-08-19 2000-10-24 Mower Family Chf Treatment Irrevocable Trust Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool
US6141587A (en) * 1996-08-19 2000-10-31 Mower Family Chf Treatment Irrevocable Trust Augmentation of muscle contractility by biphasic stimulation
US6343232B1 (en) 1966-08-19 2002-01-29 Mower Chf Treatment Irrevocable Trust Augmentation of muscle contractility by biphasic stimulation
US6044294A (en) * 1995-12-15 2000-03-28 Pacesetter, Inc. Methods and apparatus for measuring impedance in the body
US5837900A (en) * 1996-06-21 1998-11-17 Medtronic Inc System and method for detecting metal ion oxidation in pacing lead
US7203537B2 (en) 1996-08-19 2007-04-10 Mr3 Medical, Llc System and method for breaking reentry circuits by cooling cardiac tissue
US6337995B1 (en) 1996-08-19 2002-01-08 Mower Chf Treatment Irrevocable Trust Atrial sensing and multiple site stimulation as intervention for atrial fibrillation
US7440800B2 (en) * 1996-08-19 2008-10-21 Mr3 Medical, Llc System and method for managing detrimental cardiac remodeling
US6295470B1 (en) * 1996-08-19 2001-09-25 The Mower Family Chf Treatment Irrevocable Trust Antitachycardial pacing
US6341235B1 (en) 1996-08-19 2002-01-22 Mower Chf Treatment Irrevocable Trust Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool
US8447399B2 (en) * 1996-08-19 2013-05-21 Mr3 Medical, Llc System and method for managing detrimental cardiac remodeling
US5871506A (en) * 1996-08-19 1999-02-16 Mower; Morton M. Augmentation of electrical conduction and contractility by biphasic cardiac pacing
US7840264B1 (en) 1996-08-19 2010-11-23 Mr3 Medical, Llc System and method for breaking reentry circuits by cooling cardiac tissue
US7908003B1 (en) 1996-08-19 2011-03-15 Mr3 Medical Llc System and method for treating ischemia by improving cardiac efficiency
US6411847B1 (en) 1996-08-19 2002-06-25 Morton M. Mower Apparatus for applying cyclic pacing at an average rate just above the intrinsic heart rate
US5713935A (en) * 1996-08-23 1998-02-03 Sulzer Intermedics Inc. Method and apparatus for monitored biphasic cardiac impedance sensing
US5755742A (en) * 1996-11-05 1998-05-26 Medtronic, Inc. Cardioversion/defibrillation lead impedance measurement system
US6269264B1 (en) * 1996-12-13 2001-07-31 Pacesetter, Inc. Method for measuring impedance in the body
US5957861A (en) * 1997-01-31 1999-09-28 Medtronic, Inc. Impedance monitor for discerning edema through evaluation of respiratory rate
US5876353A (en) 1997-01-31 1999-03-02 Medtronic, Inc. Impedance monitor for discerning edema through evaluation of respiratory rate
US5814088A (en) * 1997-03-26 1998-09-29 Sulzer Intermedics Inc. Cardiac stimulator with lead failure detector and warning system
US5910156A (en) * 1997-11-07 1999-06-08 Medtronic Inc. Non-physiologic sense detection for implantable medical devices
US5897577A (en) * 1997-11-07 1999-04-27 Medtronic, Inc. Pacing lead impedance monitoring circuit and method
US6141585A (en) 1998-05-08 2000-10-31 Intermedics Inc. Implantable cardiac stimulator with electrode-tissue interface characterization
US7901400B2 (en) 1998-10-23 2011-03-08 Covidien Ag Method and system for controlling output of RF medical generator
US7364577B2 (en) 2002-02-11 2008-04-29 Sherwood Services Ag Vessel sealing system
US7137980B2 (en) 1998-10-23 2006-11-21 Sherwood Services Ag Method and system for controlling output of RF medical generator
US6016448A (en) * 1998-10-27 2000-01-18 Medtronic, Inc. Multilevel ERI for implantable medical devices
US5944746A (en) * 1998-10-30 1999-08-31 Pacesetter, Inc. ICD with continuous regular testing of defibrillation lead status
US6317633B1 (en) 1999-01-19 2001-11-13 Medtronic, Inc. Implantable lead functional status monitor and method
US6721600B2 (en) * 2000-01-19 2004-04-13 Medtronic, Inc. Implantable lead functional status monitor and method
US6411845B1 (en) 1999-03-04 2002-06-25 Mower Chf Treatment Irrevocable Trust System for multiple site biphasic stimulation to revert ventricular arrhythmias
US6200265B1 (en) 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
US6587719B1 (en) 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US6512949B1 (en) * 1999-07-12 2003-01-28 Medtronic, Inc. Implantable medical device for measuring time varying physiologic conditions especially edema and for responding thereto
US6370432B1 (en) * 1999-08-20 2002-04-09 Cardiac Pacemakers, Inc. Pacemaker passive measurement testing system and method
US6282446B1 (en) 1999-08-20 2001-08-28 Cardiac Pacemakers, Inc. Automatic shock lead gain adjuster
US6402741B1 (en) 1999-10-08 2002-06-11 Sherwood Services Ag Current and status monitor
US6332096B1 (en) 2000-02-16 2001-12-18 Mower Chf Treatment Irrevocable Trust Augmentation of electrical conduction and contractility by biphasic cardiac pacing
US6810286B2 (en) * 2000-03-06 2004-10-26 Medtronic, Inc Stimulation for delivery of molecular therapy
US6445952B1 (en) 2000-05-18 2002-09-03 Medtronic, Inc. Apparatus and method for detecting micro-dislodgment of a pacing lead
US6681135B1 (en) 2000-10-30 2004-01-20 Medtronic, Inc. System and method for employing temperature measurements to control the operation of an implantable medical device
US6505072B1 (en) * 2000-11-16 2003-01-07 Cardiac Pacemakers, Inc. Implantable electronic stimulator having isolation transformer input to telemetry circuits
US6609025B2 (en) 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
US6912420B2 (en) 2001-04-10 2005-06-28 Cardiac Pacemakers, Inc. Cardiac rhythm management system for hypotension
US7050851B2 (en) * 2001-06-29 2006-05-23 Medtronic, Inc. Implantable cardioverter/defibrillator with housing electrode and lead detection and switching circuitry
US6968235B2 (en) * 2001-07-17 2005-11-22 Medtronic, Inc. Enhanced method and apparatus to identify and connect a small diameter lead with a low profile lead connector
US6675049B2 (en) 2001-07-17 2004-01-06 Medtronic, Inc. Method and apparatus for automatic implantable medical lead recognition and configuration
US6748271B2 (en) * 2001-07-27 2004-06-08 Cardiac Pacemakers, Inc. Method and system for treatment of neurocardiogenic syncope
US7191000B2 (en) 2001-07-31 2007-03-13 Cardiac Pacemakers, Inc. Cardiac rhythm management system for edema
FR2834881B1 (en) * 2002-01-23 2004-10-22 Ela Medical Sa PHYSIOLOGICAL SIGNAL RECORDER, IN PARTICULAR HOLTER ECG SIGNAL RECORDER, INCLUDING MEANS OF DETECTION OF THE DISCONNECTION OR CUTTING OF THE LINK CABLES
US6978171B2 (en) * 2002-03-15 2005-12-20 Medtronic, Inc. Automated impedance measurement of an implantable medical device
US7526341B2 (en) * 2002-03-15 2009-04-28 Medtronic, Inc. Amplitude ramping of waveforms generated by an implantable medical device
US20030199938A1 (en) * 2002-04-22 2003-10-23 Karel Smits Precise cardiac lead placement based on impedance measurements
US6978178B2 (en) * 2002-04-30 2005-12-20 Medtronic, Inc. Method and apparatus for selecting an optimal electrode configuration of a medical electrical lead having a multiple electrode array
WO2003092520A1 (en) 2002-05-06 2003-11-13 Sherwood Services Ag Blood detector for controlling anesu and method therefor
US7120493B2 (en) * 2002-07-31 2006-10-10 Cardiac Pacemakers, Inc. Shock lead impedance measurement to ensure safe delivery of shock therapy to maintain circuit integrity
US7047083B2 (en) * 2002-09-30 2006-05-16 Medtronic, Inc. Method and apparatus for identifying lead-related conditions using lead impedance measurements
US7226422B2 (en) * 2002-10-09 2007-06-05 Cardiac Pacemakers, Inc. Detection of congestion from monitoring patient response to a recumbent position
US7076302B2 (en) 2002-10-10 2006-07-11 Cardiac Pacemakers, Inc. Connection verification apparatus, systems, and methods
US20040073266A1 (en) * 2002-10-15 2004-04-15 Haefner Paul A. Automatic detection of defibrillation lead
US20040088033A1 (en) * 2002-10-31 2004-05-06 Smits Karel F.A.A. Implantable medical lead designs
US8010207B2 (en) 2002-10-31 2011-08-30 Medtronic, Inc. Implantable medical lead designs
US7044948B2 (en) 2002-12-10 2006-05-16 Sherwood Services Ag Circuit for controlling arc energy from an electrosurgical generator
FR2850029B1 (en) * 2003-01-17 2005-11-18 Ela Medical Sa ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR A CARDIAC STIMULATOR, COMPRISING MEANS FOR DETERMINING THE PRESENCE AND THE TYPE OF PROBE ASSOCIATED WITH IT
US7233825B2 (en) * 2003-02-15 2007-06-19 Medtronic, Inc. Impedance measurement in implanted device
US7233826B2 (en) * 2003-04-25 2007-06-19 Medtronic, Inc. Bi-ventricular and single-ventricle pacing
US7722601B2 (en) 2003-05-01 2010-05-25 Covidien Ag Method and system for programming and controlling an electrosurgical generator system
AU2003284929B2 (en) 2003-10-23 2010-07-22 Covidien Ag Redundant temperature monitoring in electrosurgical systems for safety mitigation
US8104956B2 (en) 2003-10-23 2012-01-31 Covidien Ag Thermocouple measurement circuit
US7396336B2 (en) 2003-10-30 2008-07-08 Sherwood Services Ag Switched resonant ultrasonic power amplifier system
US7131860B2 (en) 2003-11-20 2006-11-07 Sherwood Services Ag Connector systems for electrosurgical generator
US7766905B2 (en) 2004-02-12 2010-08-03 Covidien Ag Method and system for continuity testing of medical electrodes
US7780662B2 (en) 2004-03-02 2010-08-24 Covidien Ag Vessel sealing system using capacitive RF dielectric heating
FR2873298B1 (en) * 2004-07-23 2006-09-22 Ela Medical Sa IMPLANTABLE CARDIAC STIMULATOR WITH AUTOMATIC SENSOR PLACEMENT DETECTION AND HOUSING IMPLANTATION
US7751891B2 (en) * 2004-07-28 2010-07-06 Cyberonics, Inc. Power supply monitoring for an implantable device
US7387610B2 (en) 2004-08-19 2008-06-17 Cardiac Pacemakers, Inc. Thoracic impedance detection with blood resistivity compensation
US7628786B2 (en) 2004-10-13 2009-12-08 Covidien Ag Universal foot switch contact port
US7775966B2 (en) 2005-02-24 2010-08-17 Ethicon Endo-Surgery, Inc. Non-invasive pressure measurement in a fluid adjustable restrictive device
US7699770B2 (en) 2005-02-24 2010-04-20 Ethicon Endo-Surgery, Inc. Device for non-invasive measurement of fluid pressure in an adjustable restriction device
US7927270B2 (en) 2005-02-24 2011-04-19 Ethicon Endo-Surgery, Inc. External mechanical pressure sensor for gastric band pressure measurements
US7775215B2 (en) 2005-02-24 2010-08-17 Ethicon Endo-Surgery, Inc. System and method for determining implanted device positioning and obtaining pressure data
US7658196B2 (en) 2005-02-24 2010-02-09 Ethicon Endo-Surgery, Inc. System and method for determining implanted device orientation
US8016744B2 (en) 2005-02-24 2011-09-13 Ethicon Endo-Surgery, Inc. External pressure-based gastric band adjustment system and method
US8066629B2 (en) 2005-02-24 2011-11-29 Ethicon Endo-Surgery, Inc. Apparatus for adjustment and sensing of gastric band pressure
US9474564B2 (en) 2005-03-31 2016-10-25 Covidien Ag Method and system for compensating for external impedance of an energy carrying component when controlling an electrosurgical generator
US7603170B2 (en) 2005-04-26 2009-10-13 Cardiac Pacemakers, Inc. Calibration of impedance monitoring of respiratory volumes using thoracic D.C. impedance
US7899540B2 (en) * 2005-04-29 2011-03-01 Cyberonics, Inc. Noninvasively adjustable gastric band
US7835796B2 (en) * 2005-04-29 2010-11-16 Cyberonics, Inc. Weight loss method and device
EP1883450B1 (en) * 2005-04-29 2009-12-09 Medtronic, Inc. Distributed lead functionality testing
US7310557B2 (en) * 2005-04-29 2007-12-18 Maschino Steven E Identification of electrodes for nerve stimulation in the treatment of eating disorders
WO2006119103A2 (en) 2005-04-29 2006-11-09 Medtronic, Inc. Event-based lead impedance monitoring
US7907997B2 (en) * 2005-05-11 2011-03-15 Cardiac Pacemakers, Inc. Enhancements to the detection of pulmonary edema when using transthoracic impedance
US9089275B2 (en) * 2005-05-11 2015-07-28 Cardiac Pacemakers, Inc. Sensitivity and specificity of pulmonary edema detection when using transthoracic impedance
US7340296B2 (en) 2005-05-18 2008-03-04 Cardiac Pacemakers, Inc. Detection of pleural effusion using transthoracic impedance
US7856273B2 (en) 2005-07-28 2010-12-21 Cyberonics, Inc. Autonomic nerve stimulation to treat a gastrointestinal disorder
WO2007043923A1 (en) * 2005-10-11 2007-04-19 St. Jude Medical Ab Method and implantable medical device for measuring an electrical bio-impedance of a patient
US8734438B2 (en) 2005-10-21 2014-05-27 Covidien Ag Circuit and method for reducing stored energy in an electrosurgical generator
US7567840B2 (en) 2005-10-28 2009-07-28 Cyberonics, Inc. Lead condition assessment for an implantable medical device
US7947039B2 (en) 2005-12-12 2011-05-24 Covidien Ag Laparoscopic apparatus for performing electrosurgical procedures
US7677503B2 (en) * 2005-12-30 2010-03-16 Thomas & Betts International, Inc. Rework bracket for electrical outlet boxes
US8147485B2 (en) 2006-01-24 2012-04-03 Covidien Ag System and method for tissue sealing
CA2574935A1 (en) 2006-01-24 2007-07-24 Sherwood Services Ag A method and system for controlling an output of a radio-frequency medical generator having an impedance based control algorithm
CA2575392C (en) 2006-01-24 2015-07-07 Sherwood Services Ag System and method for tissue sealing
CA2574934C (en) 2006-01-24 2015-12-29 Sherwood Services Ag System and method for closed loop monitoring of monopolar electrosurgical apparatus
US7513896B2 (en) 2006-01-24 2009-04-07 Covidien Ag Dual synchro-resonant electrosurgical apparatus with bi-directional magnetic coupling
US9186200B2 (en) 2006-01-24 2015-11-17 Covidien Ag System and method for tissue sealing
US8216223B2 (en) 2006-01-24 2012-07-10 Covidien Ag System and method for tissue sealing
US8685016B2 (en) 2006-01-24 2014-04-01 Covidien Ag System and method for tissue sealing
US7769455B2 (en) * 2006-01-27 2010-08-03 Cyberonics, Inc. Power supply monitoring for an implantable device
US7651493B2 (en) 2006-03-03 2010-01-26 Covidien Ag System and method for controlling electrosurgical snares
US7648499B2 (en) 2006-03-21 2010-01-19 Covidien Ag System and method for generating radio frequency energy
US8870742B2 (en) 2006-04-06 2014-10-28 Ethicon Endo-Surgery, Inc. GUI for an implantable restriction device and a data logger
US8152710B2 (en) 2006-04-06 2012-04-10 Ethicon Endo-Surgery, Inc. Physiological parameter analysis for an implantable restriction device and a data logger
US8180462B2 (en) 2006-04-18 2012-05-15 Cyberonics, Inc. Heat dissipation for a lead assembly
US7651492B2 (en) 2006-04-24 2010-01-26 Covidien Ag Arc based adaptive control system for an electrosurgical unit
US8753334B2 (en) 2006-05-10 2014-06-17 Covidien Ag System and method for reducing leakage current in an electrosurgical generator
US8478420B2 (en) 2006-07-12 2013-07-02 Cyberonics, Inc. Implantable medical device charge balance assessment
US20080027524A1 (en) 2006-07-26 2008-01-31 Maschino Steven E Multi-electrode assembly for an implantable medical device
US8034049B2 (en) 2006-08-08 2011-10-11 Covidien Ag System and method for measuring initial tissue impedance
US7731717B2 (en) 2006-08-08 2010-06-08 Covidien Ag System and method for controlling RF output during tissue sealing
US8343049B2 (en) 2006-08-24 2013-01-01 Cardiac Pacemakers, Inc. Physiological response to posture change
US7794457B2 (en) 2006-09-28 2010-09-14 Covidien Ag Transformer for RF voltage sensing
US7974707B2 (en) 2007-01-26 2011-07-05 Cyberonics, Inc. Electrode assembly with fibers for a medical device
US7904175B2 (en) * 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US7962214B2 (en) * 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7869884B2 (en) * 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US8777941B2 (en) 2007-05-10 2014-07-15 Covidien Lp Adjustable impedance electrosurgical electrodes
US7834484B2 (en) 2007-07-16 2010-11-16 Tyco Healthcare Group Lp Connection cable and method for activating a voltage-controlled generator
EP2190528B1 (en) 2007-08-20 2014-10-08 Medtronic, Inc. Evaluating therapeutic stimulation electrode configurations based on physiological responses
EP2195078B1 (en) 2007-08-20 2013-10-09 Medtronic, Inc. Implantable medical lead with biased electrode
WO2009025816A1 (en) * 2007-08-20 2009-02-26 Medtronic, Inc. Electrode configurations for directional leads
US8216220B2 (en) 2007-09-07 2012-07-10 Tyco Healthcare Group Lp System and method for transmission of combined data stream
US8512332B2 (en) 2007-09-21 2013-08-20 Covidien Lp Real-time arc control in electrosurgical generators
US7474247B1 (en) * 2007-09-26 2009-01-06 Medtronic, Inc. Detecting overloading of an analog-to-digital converter of an implantable medical device
US8868203B2 (en) * 2007-10-26 2014-10-21 Cyberonics, Inc. Dynamic lead condition detection for an implantable medical device
US8942798B2 (en) * 2007-10-26 2015-01-27 Cyberonics, Inc. Alternative operation mode for an implantable medical device based upon lead condition
US8187163B2 (en) 2007-12-10 2012-05-29 Ethicon Endo-Surgery, Inc. Methods for implanting a gastric restriction device
US8185203B2 (en) * 2007-12-14 2012-05-22 Cardiac Pacemakers, Inc. Vector configuration detection and corrective response systems and methods
US8100870B2 (en) 2007-12-14 2012-01-24 Ethicon Endo-Surgery, Inc. Adjustable height gastric restriction devices and methods
US8142452B2 (en) 2007-12-27 2012-03-27 Ethicon Endo-Surgery, Inc. Controlling pressure in adjustable restriction devices
US8377079B2 (en) 2007-12-27 2013-02-19 Ethicon Endo-Surgery, Inc. Constant force mechanisms for regulating restriction devices
US8591395B2 (en) 2008-01-28 2013-11-26 Ethicon Endo-Surgery, Inc. Gastric restriction device data handling devices and methods
US8192350B2 (en) 2008-01-28 2012-06-05 Ethicon Endo-Surgery, Inc. Methods and devices for measuring impedance in a gastric restriction system
US8337389B2 (en) 2008-01-28 2012-12-25 Ethicon Endo-Surgery, Inc. Methods and devices for diagnosing performance of a gastric restriction system
US8221439B2 (en) 2008-02-07 2012-07-17 Ethicon Endo-Surgery, Inc. Powering implantable restriction systems using kinetic motion
US7844342B2 (en) 2008-02-07 2010-11-30 Ethicon Endo-Surgery, Inc. Powering implantable restriction systems using light
US8114345B2 (en) 2008-02-08 2012-02-14 Ethicon Endo-Surgery, Inc. System and method of sterilizing an implantable medical device
US8255055B2 (en) * 2008-02-11 2012-08-28 Cardiac Pacemakers, Inc. MRI shielding in electrodes using AC pacing
US8591532B2 (en) 2008-02-12 2013-11-26 Ethicon Endo-Sugery, Inc. Automatically adjusting band system
US8057492B2 (en) 2008-02-12 2011-11-15 Ethicon Endo-Surgery, Inc. Automatically adjusting band system with MEMS pump
US8034065B2 (en) 2008-02-26 2011-10-11 Ethicon Endo-Surgery, Inc. Controlling pressure in adjustable restriction devices
US8187162B2 (en) 2008-03-06 2012-05-29 Ethicon Endo-Surgery, Inc. Reorientation port
US8233995B2 (en) 2008-03-06 2012-07-31 Ethicon Endo-Surgery, Inc. System and method of aligning an implantable antenna
EP2320999A1 (en) * 2008-06-02 2011-05-18 Medtronic, Inc. Sensing integrity determination based on cardiovascular pressure
US9037240B2 (en) * 2008-06-02 2015-05-19 Medtronic, Inc. Electrode lead integrity reports
WO2009148425A1 (en) * 2008-06-02 2009-12-10 Medtronic, Inc. Impedance variability analysis to identify lead-related conditions
US20090299421A1 (en) * 2008-06-02 2009-12-03 Medtronic, Inc. Evaluation of implantable medical device sensing integrity based on evoked signals
US8200322B2 (en) * 2008-06-02 2012-06-12 Medtronic, Inc. Electrogram storage for suspected non-physiological episodes
US8226639B2 (en) 2008-06-10 2012-07-24 Tyco Healthcare Group Lp System and method for output control of electrosurgical generator
US7974690B2 (en) * 2008-06-30 2011-07-05 Medtronic, Inc. Lead integrity testing during suspected tachyarrhythmias
US9522277B2 (en) 2008-07-28 2016-12-20 Medtronic, Inc. Lead integrity testing triggered by sensed signal saturation
US7953488B2 (en) * 2008-07-31 2011-05-31 Medtronic, Inc. Pre-qualification of an alternate sensing configuration
AU2009307979A1 (en) * 2008-10-23 2010-04-29 Cardiac Pacemakers, Inc. Systems and methods to detect implantable medical device configuration changes affecting MRI conditional safety
US8078277B2 (en) 2008-10-29 2011-12-13 Medtronic, Inc. Identification and remediation of oversensed cardiac events using far-field electrograms
US10118042B2 (en) 2008-10-31 2018-11-06 Medtronic, Inc. Lead integrity testing triggered by sensed asystole
US8262652B2 (en) 2009-01-12 2012-09-11 Tyco Healthcare Group Lp Imaginary impedance process monitoring and intelligent shut-off
US9084883B2 (en) 2009-03-12 2015-07-21 Cardiac Pacemakers, Inc. Thin profile conductor assembly for medical device leads
WO2011043898A2 (en) * 2009-10-09 2011-04-14 Cardiac Pacemakers, Inc. Mri compatible medical device lead including transmission line notch filters
WO2011049684A1 (en) * 2009-10-19 2011-04-28 Cardiac Pacemakers, Inc. Mri compatible tachycardia lead
US8406895B2 (en) * 2009-12-30 2013-03-26 Cardiac Pacemakers, Inc. Implantable electrical lead including a cooling assembly to dissipate MRI induced electrode heat
EP2519311A1 (en) 2009-12-30 2012-11-07 Cardiac Pacemakers, Inc. Mri-conditionally safe medical device lead
WO2011081697A1 (en) * 2009-12-30 2011-07-07 Cardiac Pacemakers, Inc. Apparatus to selectively increase medical device lead inner conductor inductance
CN102655908B (en) 2009-12-31 2015-04-22 心脏起搏器公司 MRI conditionally safe lead with multi-layer conductor
US8391994B2 (en) 2009-12-31 2013-03-05 Cardiac Pacemakers, Inc. MRI conditionally safe lead with low-profile multi-layer conductor for longitudinal expansion
US8396543B2 (en) * 2010-01-28 2013-03-12 Medtronic, Inc. Storage of data for evaluation of lead integrity
US8478428B2 (en) 2010-04-23 2013-07-02 Cyberonics, Inc. Helical electrode for nerve stimulation
US8874229B2 (en) 2010-04-28 2014-10-28 Cyberonics, Inc. Delivering scheduled and unscheduled therapy without detriment to battery life or accuracy of longevity predictions
WO2012019036A1 (en) 2010-08-06 2012-02-09 Cardiac Pacemakers, Inc. User interface system for use with multipolar pacing leads
US8825181B2 (en) 2010-08-30 2014-09-02 Cardiac Pacemakers, Inc. Lead conductor with pitch and torque control for MRI conditionally safe use
US8463384B2 (en) 2011-01-27 2013-06-11 Medtronic, Inc. Isolated lead conductor measurements for fault detection
US9539428B2 (en) 2011-01-27 2017-01-10 Medtronic, Inc. Isolating lead conductor for fault detection
US8577459B2 (en) 2011-01-28 2013-11-05 Cyberonics, Inc. System and method for estimating battery capacity
US8761884B2 (en) 2011-04-14 2014-06-24 Cyberonics, Inc. Device longevity prediction for a device having variable energy consumption
US8761885B2 (en) 2011-04-29 2014-06-24 Cyberonics, Inc. Battery life estimation based on voltage depletion rate
US8355784B2 (en) 2011-05-13 2013-01-15 Medtronic, Inc. Dynamic representation of multipolar leads in a programmer interface
US8798751B2 (en) 2011-06-09 2014-08-05 Medtronic, Inc. Method and apparatus to manage lead-related conditions for fault tolerance enhancements
US8855765B2 (en) 2011-06-09 2014-10-07 Medtronic, Inc. Fault tolerant methods and architectures for embedded intelligence in medical leads
US8577457B2 (en) 2011-07-07 2013-11-05 Medtronics, Inc. Isolating lead body for fault detection
US20130027186A1 (en) 2011-07-26 2013-01-31 Can Cinbis Ultralow-power implantable hub-based wireless implantable sensor communication
US8437840B2 (en) 2011-09-26 2013-05-07 Medtronic, Inc. Episode classifier algorithm
US8774909B2 (en) 2011-09-26 2014-07-08 Medtronic, Inc. Episode classifier algorithm
US10376301B2 (en) 2011-09-28 2019-08-13 Covidien Lp Logarithmic amplifier, electrosurgical generator including same, and method of controlling electrosurgical generator using same
US8744560B2 (en) 2011-09-30 2014-06-03 Medtronic, Inc. Electrogram summary
US9668668B2 (en) 2011-09-30 2017-06-06 Medtronic, Inc. Electrogram summary
US8521281B2 (en) 2011-10-14 2013-08-27 Medtronic, Inc. Electrogram classification algorithm
US8886296B2 (en) 2011-10-14 2014-11-11 Medtronic, Inc. T-wave oversensing
US9232898B2 (en) 2011-10-27 2016-01-12 Medtronic, Inc. Method and apparatus to manage lead-related conditions for fault tolerance enhancements
US10076383B2 (en) 2012-01-25 2018-09-18 Covidien Lp Electrosurgical device having a multiplexer
US8825179B2 (en) 2012-04-20 2014-09-02 Cardiac Pacemakers, Inc. Implantable medical device lead including a unifilar coiled cable
US9079037B2 (en) 2012-04-27 2015-07-14 Medtronic, Inc. Fault tolerant implantable medical system
US8996111B2 (en) 2012-04-27 2015-03-31 Medtronic, Inc. Lead recognition for an implantable medical system
WO2013162713A1 (en) 2012-04-27 2013-10-31 Medtronic, Inc. Fault tolerant implantable medical system
US8954168B2 (en) 2012-06-01 2015-02-10 Cardiac Pacemakers, Inc. Implantable device lead including a distal electrode assembly with a coiled component
JP6069499B2 (en) 2012-08-31 2017-02-01 カーディアック ペースメイカーズ, インコーポレイテッド Lead wire with low peak MRI heating
JP6034499B2 (en) 2012-10-18 2016-11-30 カーディアック ペースメイカーズ, インコーポレイテッド Inductive element for providing MRI compatibility in implantable medical device leads
US10556117B2 (en) 2013-05-06 2020-02-11 Medtronic, Inc. Implantable cardioverter-defibrillator (ICD) system including substernal pacing lead
US10532203B2 (en) 2013-05-06 2020-01-14 Medtronic, Inc. Substernal electrical stimulation system
US9717923B2 (en) 2013-05-06 2017-08-01 Medtronic, Inc. Implantable medical device system having implantable cardioverter-defibrillator (ICD) system and substernal leadless pacing device
US9220913B2 (en) 2013-05-06 2015-12-29 Medtronics, Inc. Multi-mode implantable medical device
US10471267B2 (en) 2013-05-06 2019-11-12 Medtronic, Inc. Implantable cardioverter-defibrillator (ICD) system including substernal lead
US9872719B2 (en) 2013-07-24 2018-01-23 Covidien Lp Systems and methods for generating electrosurgical energy using a multistage power converter
US9636165B2 (en) 2013-07-29 2017-05-02 Covidien Lp Systems and methods for measuring tissue impedance through an electrosurgical cable
US9764139B2 (en) 2014-01-24 2017-09-19 Medtronic, Inc. Pre-implant detection
US9302100B2 (en) 2014-02-13 2016-04-05 Medtronic, Inc. Lead monitoring frequency based on lead and patient characteristics
WO2015123483A1 (en) 2014-02-13 2015-08-20 Medtronic, Inc. Lead monitoring frequency based on lead and patient characteristics
US9399141B2 (en) 2014-02-13 2016-07-26 Medtronic, Inc. Lead monitoring frequency based on lead and patient characteristics
US9409026B2 (en) 2014-02-13 2016-08-09 Medtronic, Inc. Lead monitoring frequency based on lead and patient characteristics
EP3110499B1 (en) 2014-02-26 2018-01-24 Cardiac Pacemakers, Inc. Construction of an mri-safe tachycardia lead
US9694187B2 (en) 2014-07-16 2017-07-04 Cardiac Pacemakers, Inc. Implantable medical devices and methods including post-procedural system diagnostics
CA2959183C (en) 2014-09-04 2023-10-10 AtaCor Medical, Inc. Receptacle for pacemaker lead
US10743960B2 (en) 2014-09-04 2020-08-18 AtaCor Medical, Inc. Cardiac arrhythmia treatment devices and delivery
US9636505B2 (en) 2014-11-24 2017-05-02 AtaCor Medical, Inc. Cardiac pacing sensing and control
US10328268B2 (en) 2014-09-04 2019-06-25 AtaCor Medical, Inc. Cardiac pacing
US9636512B2 (en) 2014-11-05 2017-05-02 Medtronic, Inc. Implantable cardioverter-defibrillator (ICD) system having multiple common polarity extravascular defibrillation electrodes
US11097109B2 (en) 2014-11-24 2021-08-24 AtaCor Medical, Inc. Cardiac pacing sensing and control
WO2020243534A1 (en) 2019-05-29 2020-12-03 AtaCor Medical, Inc. Implantable electrical leads and associated delivery systems
US11666771B2 (en) 2020-05-29 2023-06-06 AtaCor Medical, Inc. Implantable electrical leads and associated delivery systems
WO2023175440A1 (en) 2022-03-16 2023-09-21 Medtronic, Inc. Medical device with detection of an integrated or true bipolar lead for selecting operating parameters

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249819A1 (en) * 1986-06-16 1987-12-23 Pacesetter AB Cardiac pacer for pacing a human heart
EP0311019A1 (en) * 1987-10-07 1989-04-12 Siemens-Elema AB Pacer for stimulating a heart synchronous to atrial activity
EP0557550A1 (en) * 1992-02-26 1993-09-01 Pacesetter AB Rate adaptive cardiac pacemaker
WO1995009028A2 (en) * 1993-09-21 1995-04-06 Pacesetter, Inc. Automatic implantable pulse generator
US5413593A (en) * 1994-01-31 1995-05-09 Cardiac Pacemakers, Inc. Using sub-threshold unipolar pacing markers to improve the interpretation of surface EKG in pacemaker patients
US5431692A (en) * 1993-08-02 1995-07-11 Telectronics Pacing Systems, Inc. Method and apparatus for testing compatibility of lead polarity and polarity programming of a cardiac stimulator

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965418A (en) * 1973-11-01 1976-06-22 Wiltron Company Telephone system testing apparatus and techniques utilizing central measuring equipment with a plurality of remote test stations
US4958632A (en) * 1978-07-20 1990-09-25 Medtronic, Inc. Adaptable, digital computer controlled cardiac pacemaker
US4250884A (en) * 1978-11-06 1981-02-17 Medtronic, Inc. Apparatus for and method of programming the minimum energy threshold for pacing pulses to be applied to a patient's heart
US4476868A (en) * 1978-11-06 1984-10-16 Medtronic, Inc. Body stimulator output circuit
US4290430A (en) * 1980-06-05 1981-09-22 Intermedics, Inc. Pacer analyzer
US4556063A (en) * 1980-10-07 1985-12-03 Medtronic, Inc. Telemetry system for a medical device
US4374382A (en) * 1981-01-16 1983-02-15 Medtronic, Inc. Marker channel telemetry system for a medical device
DE3775281D1 (en) * 1986-06-16 1992-01-30 Siemens Ag DEVICE FOR CONTROLLING A HEART PACER BY MEANS OF IMPEDANCE ON BODY TISSUES.
US4901725A (en) * 1988-01-29 1990-02-20 Telectronics N.V. Minute volume rate-responsive pacemaker
US4899750A (en) * 1988-04-19 1990-02-13 Siemens-Pacesetter, Inc. Lead impedance scanning system for pacemakers
US5003975A (en) * 1988-04-19 1991-04-02 Siemens-Pacesetter, Inc. Automatic electrode configuration of an implantable pacemaker
AU614118B2 (en) * 1988-04-19 1991-08-22 Pacesetter Ab Configuration programming of an implantable pacemaker
US4951682A (en) * 1988-06-22 1990-08-28 The Cleveland Clinic Foundation Continuous cardiac output by impedance measurements in the heart
US4964407A (en) * 1988-08-29 1990-10-23 Intermedics, Inc. Method and apparatus for assuring pacer programming is compatible with the lead
US5052388A (en) * 1989-12-22 1991-10-01 Medtronic, Inc. Method and apparatus for implementing activity sensing in a pulse generator
US5127404A (en) * 1990-01-22 1992-07-07 Medtronic, Inc. Telemetry format for implanted medical device
US5201808A (en) * 1992-02-10 1993-04-13 Telectronics Pacing Systems, Inc. Minute volume rate-responsive pacemaker employing impedance sensing on a unipolar lead

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249819A1 (en) * 1986-06-16 1987-12-23 Pacesetter AB Cardiac pacer for pacing a human heart
EP0311019A1 (en) * 1987-10-07 1989-04-12 Siemens-Elema AB Pacer for stimulating a heart synchronous to atrial activity
EP0557550A1 (en) * 1992-02-26 1993-09-01 Pacesetter AB Rate adaptive cardiac pacemaker
US5431692A (en) * 1993-08-02 1995-07-11 Telectronics Pacing Systems, Inc. Method and apparatus for testing compatibility of lead polarity and polarity programming of a cardiac stimulator
WO1995009028A2 (en) * 1993-09-21 1995-04-06 Pacesetter, Inc. Automatic implantable pulse generator
US5413593A (en) * 1994-01-31 1995-05-09 Cardiac Pacemakers, Inc. Using sub-threshold unipolar pacing markers to improve the interpretation of surface EKG in pacemaker patients

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9302101B2 (en) 2004-03-30 2016-04-05 Medtronic, Inc. MRI-safe implantable lead
US10084250B2 (en) 2005-02-01 2018-09-25 Medtronic, Inc. Extensible implantable medical lead
US7930028B2 (en) 2006-10-20 2011-04-19 Biotronik Crm Patent Ag Implantable cardiac device with a shock lead
EP1913971A1 (en) * 2006-10-20 2008-04-23 BIOTRONIK CRM Patent AG Implantable cardiac device with a shock lead
US10398893B2 (en) 2007-02-14 2019-09-03 Medtronic, Inc. Discontinuous conductive filler polymer-matrix composites for electromagnetic shielding
WO2008130409A1 (en) 2007-04-20 2008-10-30 Medtronic, Inc. Implantable medical electrical lead and connector assembly
US8433422B2 (en) 2007-04-20 2013-04-30 Medtronic, Inc. Implantable medical electrical lead and connector assembly
US9259572B2 (en) 2007-04-25 2016-02-16 Medtronic, Inc. Lead or lead extension having a conductive body and conductive body contact
US9731119B2 (en) 2008-03-12 2017-08-15 Medtronic, Inc. System and method for implantable medical device lead shielding
US9205253B2 (en) 2009-04-30 2015-12-08 Medtronic, Inc. Shielding an implantable medical lead
US9272136B2 (en) 2009-04-30 2016-03-01 Medtronic, Inc. Grounding of a shield within an implantable medical lead
US9452284B2 (en) 2009-04-30 2016-09-27 Medtronic, Inc. Termination of a shield within an implantable medical lead
US9629998B2 (en) 2009-04-30 2017-04-25 Medtronics, Inc. Establishing continuity between a shield within an implantable medical lead and a shield within an implantable lead extension
US9220893B2 (en) 2009-04-30 2015-12-29 Medtronic, Inc. Shielded implantable medical lead with reduced torsional stiffness
US10035014B2 (en) 2009-04-30 2018-07-31 Medtronic, Inc. Steering an implantable medical lead via a rotational coupling to a stylet
US9216286B2 (en) 2009-04-30 2015-12-22 Medtronic, Inc. Shielded implantable medical lead with guarded termination
US10086194B2 (en) 2009-04-30 2018-10-02 Medtronic, Inc. Termination of a shield within an implantable medical lead
US9186499B2 (en) 2009-04-30 2015-11-17 Medtronic, Inc. Grounding of a shield within an implantable medical lead
US9463317B2 (en) 2012-04-19 2016-10-11 Medtronic, Inc. Paired medical lead bodies with braided conductive shields having different physical parameter values
US9993638B2 (en) 2013-12-14 2018-06-12 Medtronic, Inc. Devices, systems and methods to reduce coupling of a shield and a conductor within an implantable medical lead
US10279171B2 (en) 2014-07-23 2019-05-07 Medtronic, Inc. Methods of shielding implantable medical leads and implantable medical lead extensions
US10155111B2 (en) 2014-07-24 2018-12-18 Medtronic, Inc. Methods of shielding implantable medical leads and implantable medical lead extensions

Also Published As

Publication number Publication date
AU4406696A (en) 1996-06-19
US5534018A (en) 1996-07-09

Similar Documents

Publication Publication Date Title
US5534018A (en) Automatic lead recognition for implantable medical device
EP1594568B1 (en) Impedance measurement in implanted device
US5003975A (en) Automatic electrode configuration of an implantable pacemaker
US6317633B1 (en) Implantable lead functional status monitor and method
US6928325B2 (en) Cardiac rhythm management system and method
US7515961B2 (en) Method and apparatus for dynamically monitoring, detecting and diagnosing lead conditions
US5766229A (en) Capture verification method and apparatus for implantable pacemaker utilizing heart rhythm stability measurements to minimize the likelihood of fusion
EP0794814B1 (en) Apparatus for automatic pacing threshold determination
US9539428B2 (en) Isolating lead conductor for fault detection
US5529578A (en) Cardiac pacemaker with triggered magnet modes
WO2006036667A1 (en) Implantable medical lead
WO2011053385A1 (en) Detecting lead related condition during delivery of therapeutic electrical signals
US5549653A (en) Muscle stimulation electrode for implantable cardial stimulation device with warning system
EP0338363B1 (en) Configuration programming of an implantable pacemaker
WO2002018009A1 (en) Implantable lead functional status monitor and method
JPH05500180A (en) Medical device for stimulation of tissue contraction
US5630838A (en) Muscle stimulation electrode for implantable cardiac stimulation device with warning system
US20240075298A1 (en) Implantable medical device employing an automatic adjustment of sensing and stimulation parameters upon switching from a bipolar operational mode to a unipolar operational mode
US20230149721A1 (en) Implantable pacemaker with automatic implant detection and system integrity determination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA